Clinical Digest: Recent Clinical Trials on Tuberculosis (2026-04)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to Tuberculosis. These trials are organized by their release dates for your convenience. (Last updated on: 2026-04-06)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on Tuberculosis (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | A Retrospective / Prospective Cohort Study to Evaluate The Incidence, Diagnostic Features, Clinical Course and Treatment Strategies in Histologically Confirmed Idiopathic Granulomatous Mastitis PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory breast condition with unknown cause, affecting approximately 2.4 per 100,000 women aged 20-40 years. Patients experience severe local symptoms including pain, redness, and recurrent abscesses that can last weeks to months and often mimic inflammatory breast cancer. Due to its rarity, mostly case reports and case series exist in the literature, leading to limited knowledge about risk factors, optimal treatment strategies, and clinical outcomes. The GRAMAREG study is the first European registry for patients with histologically confirmed idiopathic granulomatous mastitis. This retrospective/prospective observational cohort study aims to systematically evaluate the incidence, … |
EUROPEAN BREAST CANCER RESEARCH ASSOCIATION OF SURGICAL TRIALISTS | 2026-02-27 |
| 2 | Creation of A Cohort of Patients With Tuberculosis or Suspected Tuberculosis Admitted to A University Hospital in A Low-endemic Setting, Development of A Clinical-epidemiological Score Predictive of Tuberculosis, Optimization of The Diagnostic-therapeutic Pathway PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Despite being a curable and preventable disease, tuberculosis still represents a major global health problem. It is estimated that 10.8 million people contracted tuberculosis in 2023, with an incidence of 134 per 100,000 inhabitants. In 2023, there were 1.25 million deaths, confirming this disease as a leading cause of death and the leading cause of death from a single infectious agent. It is a disease that primarily affects adults in their most productive years, with significant repercussions on family budgets. The aim of this study is to identify and characterize the demographic, epidemiological, microbiological, clinical, … |
ANTONELLA CINGOLANI; | 2026-03-20 |
| 3 | Randomized, Double-Blind, Single-Simulation, Multicenter Clinical Study Evaluating The Efficacy and Safety of FuKe Qianjin Capsules in Combination With Antibiotics for The Treatment of Chronic Endometritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized, double-blind, single-dummy, multicenter clinical study, led by Principal Investigator Xue Fengxia at Tianjin Medical University General Hospital (sponsor and primary trial institution) and funded by Zhuzhou Qianjin Pharmaceutical Co., Ltd., evaluates the safety and efficacy of FuKe Qianjin Capsules combined with standard antibiotic therapy for chronic endometritis (CE) in women aged 20-40 years. CE, a common gynecological inflammation marked by uterine plasma cell infiltration from bacterial infection, is linked to infertility, repeated implantation failure (RIF), and recurrent miscarriage (RM); it is often underdiagnosed due to non-specific symptoms, … |
FENGXIA XUE; | 2026-03-20 |
| 4 | STeroids and Enhanced Spectrum Antibiotics for The Treatment of Patients in Africa With Refractory Sepsis (STARS Trial) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Sepsis, a life-threatening condition due to a dysregulated response to infection, is the leading cause of global mortality and is frequently driven by tuberculosis (TB) and drug-resistant bacteria in sub-Saharan Africa, particularly among people living with HIV. The current standard of care in the region, ceftriaxone, is insufficient as it does not address TB, drug-resistant bacteria, or adrenal insufficiency, which is common in HIV-related sepsis. Therefore, … |
SCOTT HEYSELL; | 2026-01-12 |
| 5 | Feasibility of The Application of A New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France – FAST-MDR PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional regimen in a French historical cohort of MDR-TB patients (2006-2022). In light of recent WHO recommendations suggesting using BPaLM as a first choice for routine MDR-TB treatment and of the expected benefits of BPaLM over the standard treatment, there will be no internal comparator arm in the study. |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2026-03-20 |
| 6 | Plasma and Breastmilk Exposures to Antituberculosis Drugs in Breastfeeding Women: An Open-label, Randomized, Six-arm, Single-dose, Pharmacokinetic Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a sub-study of the SSTARLET trial (NCT06498414). The overall aim is to assess the pharmacokinetic profiles after taking a single dose of rifampicin, isoniazid, levofloxacin, rifapentine, and bedaquiline in breastfeeding women and the excretion of these drugs in breast milk, with the hope of including breastfeeding women in future clinical trials of TPT, including expanding the inclusion criteria of the SSTARLET trial. In this study, healthy breastfeeding women who fulfill the eligibility criteria will be enrolled from several primary health care centers in Bandung, which will be referred to the TB Research Clinic of the Universitas Padjadjaran, … |
DICK MENZIES; | 2026-02-10 |
| 7 | A Multicenter, Open-label, Randomized, Active-controlled, Phase 2a Study to Evaluate The Pharmacokinetics and Safety of Alpibectir/Ethionamide in Combination With The Standard Regimen in Patients With Tuberculosis Meningitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity. The current trial aims to assess the plasma and CSF PK, as well as the safety and tolerability of alpibectir and three doses of Eto in patients with newly diagnosed TBM. Additionally, it is attended to investigate the effect of AlpE on the PK and efficacy of DTG during the first month of antiretroviral treatment (ART) for Human Immunodeficiency Virus (HIV)-positive patients. |
BIOVERSYS AG | 2026-03-03 |
| 8 | Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB PURE) A Randomized Multi-Centre Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Individual-level, unblinded randomized controlled trial of an 8-week (short arm) or 24-week (extended arm) pulmonary rehabilitation program, relative to standard of care, to prevent post-tuberculosis respiratory morbidity. Randomization will occur in a 1:1:1 ratio at the initiation of treatment. |
AKSHAY GUPTE; | 2026-03-27 |
| 9 | Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This cluster-randomized trial in Uganda will evaluate the effectiveness and implementation of a novel, peer-led TB education and counseling strategy to improve outcomes among persons with tuberculosis (TB) with and without HIV/AIDS and assess the social-behavioral mechanisms underlying the observed treatment effects. |
J. LUCIAN DAVIS; | 2026-03-20 |
| 10 | Biodistribution and Pathophysiology Study of 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung disease and fibrosis in TB patients. Microbiologically confirmed patients with active tuberculosis will be invited to participate in the study. A whole-body PET scan will be performed after 18F-FAPI-74 intravenous injection and correlation will be made with sites of TB lesions noted on CT. It is anticipated that 18F-FAPI-74 PET will be able to detect fibrosis (with high sensitivity) in the TB lesions. |
SANJAY JAIN; | 2026-03-31 |
| 11 | Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia; Work Package 3: Cluster Randomised Controlled Trial of A Diagnostic Package to Increase The Number of Tuberculosis Cases Notified PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this cluster-randomised controlled trial (CRCT) is to learn whether the use of new non-sputum-based diagnostic tests and other intervention components for tuberculosis (TB) diagnosis in healthcare facilities (HCF) can increase TB notifications. The main questions it aims to answer are: (1) Does the diagnostic intervention package raise TB notifications by HCF?; (2) Does the diagnostic intervention package raise the proportion of patients with TB who are diagnosed with microbiological tests, lower the time needed for TB diagnosis, lower the number of visits to HCF before TB diagnosis, raise the use of TB tests by healthcare providers, … |
BACHTI ALISJAHBANA; | 2026-02-10 |
| 12 | Evaluating The Performance, Feasibility, Acceptability and Cost Effectiveness of Concurrent Testing Including Novel Diagnostics, Non-sputum Specimens and Computer-aided Detection Interpretation of Chest X-ray for Childhood Tuberculosis in Bangladesh, Cameroon, Kenya and Viet Nam PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Start4Kids: Evaluating the performance, feasibility, acceptability and cost effectiveness of computer-aided detection (CAD) of chest X-ray (CXR) and concurrent testing using novel diagnostics and non-sputum specimens for childhood tuberculosis (TB) in Bangladesh, Cameroon, Kenya and Viet Nam. |
LIVERPOOL SCHOOL OF TROPICAL MEDICINE | 2025-11-25 |
| 13 | Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Identifying and validating molecular biomarkers associated with tumor-related anxiety and depression. By integrating psychological assessment data from clinical tumor patients with molecular detection results, and utilizing clinically accessible samples such as tumor tissues and sera from clinical cohorts, this study aims to clinically validate the tumor-derived proteins previously identified by our team as having potential regulatory roles. The goal is to clarify the clinical value of tumor-derived proteins as molecular biomarkers for tumor-related anxiety and depression, providing a molecular basis for early screening and risk stratification. Alternatively, … |
YINGHUA JI; | 2026-03-17 |
| 14 | Therapeutic Drug Monitoring for Linezolid in The Treatment of Rifampin-resistant Tuberculosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a two-arm, pragmatic, open-label, randomized clinical trial to determine the efficacy of Therapeutic Drug Monitoring (TDM) in preventing premature discontinuation of Linezolid (LZD) in participants with Rifampicin-resistant tuberculosis (RR-TB). Following the initiation of treatment, participants will be monitored throughout the approximate 6-month duration of RR-TB therapy. |
JAMES CM BRUST; | 2026-01-23 |
| 15 | Correlation Between Types of Tuberculosis, Spirometry Result, and Functional Capacity Based on The 6-Minute Walk Test (6MWT) in Adolescents With Post-Tuberculosis Lung Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Post-Tuberculosis Lung Disease (PTLD) is defined as chronic respiratory impairment due to previous pulmonary TB. Children recovering from pulmonary TB undergo ongoing respiratory health challenges, including more frequent respiratory symptoms, reduced lung volumes, … |
IRMA R DEFI; | 2026-03-05 |
| 16 | Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia: A Protocol for A Cluster- Randomized Controlled Trial Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study might come up with valuable findings to address poor treatment outcome, poor quality of life, disability score and depressive symptoms. The findings may also be decreased health professional workload. The findings would be supportive evidences for policy makers, program managers, to clinician as well as the patients themselves and for other researchers. The study may help to promote and maintain good treatment outcome for the patients in the study area as well as the country. The findings will also be used for teaching \& learning purposes in educational \& training programs. |
BAHIRDAR UNIVERSITY | 2026-02-19 |
| 17 | Acetohydroxamic Acid Combined With A Short-Course Regimen for The Treatment of Multidrug-Resistant Tuberculosis: A Phase II Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug-resistant tuberculosis (MDR-TB). The primary objectives are to assess the safety and tolerability of AHA combined with short-course regimens, and to determine the recommended phase II dose (RP2D) of AHA. The secondary objectives include evaluating the 8-week sputum culture conversion rate, pharmacokinetic parameters, and exploring DNA damage repair biomarkers as potential indicators of treatment response. |
YIDIAN LIU; | 2026-02-06 |
| 18 | A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE. ID93 + GLA-SE has been used in humans in research but has not been approved for use in medical care. This study will be the first to test ID93 + GLA-SE in people living with HIV (PLWH). The injections during the study will be given to different groups of participants while they are using standard TB treatment. One of the research questions is to understand the differences in immune system responses depending on the timing of giving the injections after people begin taking standard TB treatment. Researchers also want to continue to look at whether the study vaccine is safe when tested in a larger group of people, and if getting the study vaccine in addition to standard TB treatment can help to lower the number of poor TB outcomes that people might have. |
ADVANCING CLINICAL THERAPEUTICS GLOBALLY FOR HIV/AIDS AND OTHER INFECTIONS | 2025-11-13 |
| 19 | A Prospective, Randomized Controlled Clinical Study of The Effect of Remimazolam on The Incidence of Hypoxia in High-risk Patients Undergoing Painless Tracheoscopy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient, making the patient highly susceptible to respiratory and cardiovascular risks. Among these risks, hypoxia is the most common adverse event.Different drug regimens can be selected for anesthesia under deep sedation. The combination of analgesic agents can help reduce coughing during bronchoscopy. Therefore, we employ a combination of sedative and analgesic drugs for painless bronchoscopy procedures. Among sedatives, propofol is the most commonly used. However, … |
YUEYING ZHENG; | 2026-02-24 |
| 20 | Role of Endoscopic Ultrasound Elastography in Diagnosis of Gastrointestinal Subepithelial and Mediastinal Lesions PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to evaluate the role of endoscopic ultrasound (EUS) in the diagnosis of mediastinal and gastrointestinal subepithelial lesions. The study also aims to assess the diagnostic accuracy of endoscopic ultrasound (EUS) elastography in differentiating benign from malignant mediastinal and gastrointestinal subepithelial lesions. |
ABANOUB AYOUB MELK; | 2026-02-18 |
| 21 | Assessing The Burden of Tuberculosis Among Pregnant and Postpartum Women: Implications for Integrating Tuberculosis Screening Into Routine Antenatal Care in Guinea-Bissau PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to address critical diagnostic and data gaps in tuberculosis (TB) care among pregnant and postpartum women in Guinea-Bissau, a high-burden, resource-limited setting. Recognising that current TB screening during antenatal care (ANC) relies largely on unstructured symptom questions, the study will integrate more systematic and innovative approaches into routine maternal health services. The project will implement the Bandim TBscore II as a structured triage tool to classify symptom severity and guide referrals. To strengthen diagnostic capacity, … |
FRAUKE RUDOLF; | 2026-02-19 |
| 22 | Mycobacterium Tuberculosis Complex Cell-free DNA (Mtb-cfDNA) for The Pharmacometric Assessment of Anti-tuberculosis Treatment: A Proof-of-concept Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is a leading infectious cause of death worldwide. Current strategies for monitoring TB treatment response are culture dependent and insensitive. New methods of assessing treatment response in vivo could inform new drug development and other treatment strategies. Cell-free DNA (cfDNA) – small circulating fragments of DNA – … |
TIMOTHY SEERS; | 2026-01-08 |
| 23 | Investigation of The Effects of Oxidized Antigens on The T-Cell Response and The Epigenetic Reprogramming of Neutrophils in Lung Diseases – OXIGENE – PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses. |
JAN HEYCKENDORF; | 2026-02-04 |
| 24 | A Phase 2b Randomised Placebo Controlled Trial of Valganciclovir for Cytomegalovirus Viraemia in Adults and Adolescents With Advanced HIV Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if valganciclovir works to treat cytomegalovirus (CMV) infection in people with advanced HIV disease. It will also look at the safety of valganciclovir and how the body handles the drug. The main questions this study aims to answer are: Does valganciclovir safely lower the amount of CMV virus in the blood of people with advanced HIV disease? What medical problems or side effects do participants have when taking valganciclovir? Researchers will compare valganciclovir to a placebo (a look-alike tablet that does not contain any active drug) to see if valganciclovir works better than no treatment for CMV. Who can take part Adults and adolescents (15 years and older) who: Are living with HIV Have a CD4 count of 100 or less (meaning their immune system is very weak) Have CMV detected in their blood People who are pregnant, breastfeeding, very unwell, or have certain blood or kidney problems cannot take part. What will happen in the study Participants will: Be randomly assigned (like flipping a coin) to take either valganciclovir 900 mg or a placebo once a day for 4 weeks Continue to receive standard medical care for HIV and any other infections Be followed for 12 weeks after starting the study treatment During this time, participants will: Have blood tests to check CMV, HIV, and general health Have regular medical check-ups (daily in hospital, then at weeks 1, 2, 3, 4, 8, and 12) Be monitored closely for side effects, such as low blood counts or kidney problems Why this study is important Even though HIV treatment is widely available, many people still come to hospital with advanced HIV disease. In this group, about one in five people die despite starting antiretroviral therapy (ART). Reactivation of CMV is very common in these patients and has been linked to a higher risk of death. Valganciclovir is a medicine that stops CMV from multiplying. If it proves to be safe and effective in this study, it could become part of routine care to help reduce deaths in people with advanced HIV disease. Study design Type: Phase 2b, double-blind, randomised, placebo-controlled trial Sites: Helen Joseph Hospital (South Africa) and Mulago National Referral Hospital (Uganda) Number of participants: 150 (130 in the main trial, 20 in a smaller sub-study) Duration: Each participant will be followed for 12 weeks; total study duration about 2 years Possible risks and benefits Risks: Valganciclovir can cause low white blood cells, anaemia, or low platelets. These effects will be checked for regularly, and treatment will be stopped if unsafe levels are found. Benefits: The study may or may not directly benefit participants. However, it could provide important information that helps improve care for people with advanced HIV disease in the future. Oversight and safety The study is being conducted by researchers in Uganda, South Africa, the UK, and the USA, and follows international Good Clinical Practice (GCP) guidelines. An independent Data Safety and Monitoring Committee (DSMC) will regularly review safety information to protect participants. |
WITS HEALTH CONSORTIUM PTY | 2026-01-30 |
| 25 | Effects of The Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy on Sputum Secretion, Dyspnea, and Functional Capacity in Children With Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study design will be a randomized controlled trial. The data will be collected from Gulab Devi Teaching Hospital, Lahore. 34 kids aged 8 to 14 years will be randomly assigned either to an experimental group or a control group. The intervention group includes the active Cycle of Breathing technique with balloon-blowing therapy for 3 days. The control group includes the active cycle of breathing technique. Sputum secretion will be measured by ‘sputum measurement cups. Dyspnea will be measured by the Modified Borg dyspne Scale, and functional capacity will be measured by the 6-Minute Walk Test. Data will be analyzed through SPSS version 25.0. |
NAYAB SHAHID; | 2026-03-20 |
| 26 | Digital Health Intervention in Improving Preventive Treatment Initiation and Completion Among Close Contacts of Tuberculosis Patients in South Ethiopia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Despite the evidence of the prevention and control measures of tuberculosis (TB), it still has an impact on the health, social, and economic aspects of the population. Specifically, tuberculosis in children and newly diagnosed TB cases show there is current transmission of TB; to reduce this transmission and to attain the end TB strategy, preventing household TB transmission plays a great role. However, initiation and completion of TB preventive therapy (TPT) among close contacts of index TB patients are suboptimal. Some of the identified factors of low TPT initiation and completion are insufficient patient education, inadequate understanding of TPT, … |
GISTANE AYELE; | 2026-01-02 |
| 27 | Population Pharmacokinetics and Pharmacodynamics of Standard First Line Anti-TB Versus Atorvastatin-Containing Regimens in The Treatment of Pulmonary Tuberculosis: A Sub-study of The ATORTUB Phase 2C Randomized Controlled Trial (ATORTUB PopPK-PD Study) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess pharmacokinetic parameters of atorvastatin at different doses when combined with the standard first line tuberculosis (TB) treatment regimen in adults with drug sensitive pulmonary TB. The pharmacokinetics parameters will be correlated with Pharmcodynamic measures and a PK/PD model that will identify an optimal dosing regimen of atorvastatin that is appropriate for the treatment of pulmonary tuberculosis will be developed. |
ADEWOLE OLUFEMI; | 2026-01-23 |
| 28 | A Randomized Controlled Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery (TB-MET-NAC) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication. |
ROBERT WALLIS; | 2025-08-22 |
| 29 | Liquid Biopsy By Measuring Pleural Fluid Mycobacterium Tuberculosis Cell-free DNA (MTB CfDNA) Level to Diagnose Tuberculous Pleuritis in A Real-world Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is an endemic infectious disease in Hong Kong and a global health threat. Tuberculous pleuritis (TBP) is the most common form of extrapulmonary tuberculosis in China. Its presentation is frequently non-specific and the diagnosis is challenging due to its paucibacillary nature. Various studies have shown that there are limitations for conventional diagnostic modalities, including low sensitivity for pleural fluid microbiological tests (acid-fast bacilli \[AFB\] stain, Mycobacterium tuberculosis \[MTB\] culture and MTB polymerase chain reaction \[PCR\]), lack of specificity for pleural fluid biomarkers (adenosine deaminase) especially in low TB prevalence regions, invasiveness for pleural biopsy (AFB stain, … |
KA PANG CHAN; | 2025-12-16 |
| 30 | Evaluating The PATHFAST TB LAM Ag Assay As A Treatment Monitoring Tool for Pulmonary Tuberculosis: A Prospective Longitudinal Study in Nairobi, Kenya PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) can be treated; however, the standard 6-month treatment is long and challenging for many patients, and 10-20% still don’t recover well by the end of treatment. Thus, it’s important to regularly check if the treatment is working to help patients get better and prevent drug-resistant TB from developing. It can, however, be especially hard to check if TB treatment is working in places with limited resources. Traditional methods, such as testing sputum samples for microscopy and culture, have limitations. Lipoarabinomannan (LAM) is a substance that is found in the cell wall of the bacteria that cause TB, … |
NOBUO SAITO; | 2025-09-12 |
| 31 | Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic lung infection caused by environmental mycobacteria. The clinical course of NTM-PD varies widely among patients. Some individuals remain stable for long periods without treatment, while others experience worsening lung disease that requires antibiotic therapy or may lead to death. Currently available clinical tools are limited in their ability to predict which patients will experience disease progression. This observational study aims to better understand how the body’s immune response and nutritional status are related to disease progression in adults with confirmed or suspected NTM-PD. In particular, the study focuses on T cells, … |
DEOG KYEOM KIM; | 2026-01-23 |
| 32 | Study on The Correlation Between Metabolomics and Anxiety and Depression in Bronchiectasis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Bronchiectasis is a common lung disease. Approximately 20-40% of patients with bronchiectasis experience comorbid anxiety and depression. Multiple studies have now demonstrated that anxiety and depression are associated with an increased risk of disease exacerbation in these individuals. Therefore, this study aims to collect data on anxiety and depression status, disease exacerbation frequency, hospitalisation rates, and mortality among participants diagnosed with bronchiectasis. Concurrently, biological samples including blood, sputum, and stool will be obtained. Through metabolomics analysis, we will investigate the expression of anxiety and depression-related metabolic pathways and identify corresponding biomarkers to explore their role in the progression of bronchiectasis. |
WANG XIAORONG; | 2025-12-18 |
| 33 | An Evaluation of New TB Diagnostic Tests (NATs) for Active Case Finding for TB in Pakistan PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to test new diagnostic methods for tuberculosis (TB) testing as compared to the existing Xpert MTB/Rif Ultra testing approach. The research questions that will be addressed by this study include: * What are the sensitivity and specificity of the new diagnostic tests Pluslife MTBC and Ustar PortNAT for tuberculosis and how do these compare to Xpert Ultra? * How does the new diagnostic method compare to Xpert Ultra in terms of implementation feasibility, … |
MERCY CORPS PAKISTAN | 2026-01-02 |
| 34 | Infection Outcomes Among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025 PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn’s Disease (CD). This is happening because people are living longer and because more people overall are developing UC or CD. Medicines that treat UC/CD, however, … |
TAKEDA | 2026-04-02 |
| 35 | A Prospective, Single-center, Randomized Controlled Clinical Study to Evaluate The Efficacy and Safety of The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This prospective, single-center, non-inferiority, randomized controlled clinical trial aims to evaluate the efficacy and safety of a percutaneous interventional surgical control system in performing percutaneous needle biopsy of pulmonary nodules, compared with conventional manual biopsy. The study will be conducted at Shanghai Chest Hospital and plans to enroll 158 patients who meet the indications for percutaneous transthoracic needle biopsy (PTNB) and have no contraindications. Participants will be randomly assigned to one of two groups: the experimental group will undergo PTNB assisted by the percutaneous interventional surgical control system, … |
JIAYUAN SUN; | 2025-12-11 |
| 36 | Study of The Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients Using Tuberculin Skin Test at Sohag University Hospital PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This observational cross-sectional study aims to determine the prevalence of latent tuberculosis infection (LTBI) among patients undergoing regular hemodialysis at Sohag University Hospital, using the tuberculin skin test (TST). Identifying the burden of LTBI in this high-risk population will help guide early detection and preventive strategies |
FATMA AHMED IBRAHIM; | 2025-10-07 |
| 37 | Sedation of Remazolam in Combination With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery: A Single-blind, Randomized, Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Non-intubated Thoracoscopic surgery (NITS) is a newly emerging minimally invasive surgical technique in recent years . Compared with traditional intubation general anesthesia, it has the advantages of less trauma, faster recovery and fewer complications . This surgical method allows patients to perform under local anesthesia or regional block and moderate sedation, providing a physiologic ventilation method , reducing the intervention on the respiratory system and conducive to rapid postoperative recovery. The importance of sedative drugs in non-intubated thoracoscopic surgery Successful implementation of non-intubated thoracoscopic surgery requires sound regional block, airway management, … |
JIANBO WU; | 2025-07-24 |
| 38 | Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if the all-oral, shorter-course BLMZ regimen can treat Rifampicin-Resistant Tuberculosis (RR-TB) in Chinese participants aged 12 years and older. The main questions it aims to answer are: What is the proportion of participants with a favorable outcome at 18 months after starting the BLMZ regimen? What is the safety profile of the BLMZ regimen, as measured by the incidence of Grade 3 or higher adverse events and serious adverse events during the treatment period? This is a single-arm study, … |
CHU NAIHUI; | 2025-12-08 |
| 39 | A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing The Efficacy and Safety of Obinutuzumab in The Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Cryoglobulinemic vasculitis (CV) is a rare life threatening systemic immune-complex-mediated vasculitic syndrome. Symptoms range from arthralgia, purpura to more severe manifestations such as peripheral neuropathy, glomerulonephritis, and skin necrosis.1 CV is associated with significant morbidity and mortality. The management of non-infectious mixed CV is currently based on steroids, and anti-CD20 monoclonal antibody Rituximab (RTX). Infectious complications of immunosuppressants (IS) remain the main cause of death in CV. During the last decade, studies reported efficacy of RTX in patients with CV in 65-70% of patients as compared to 30% for other IS (azathioprine…). However, … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2025-12-05 |
| 40 | Hospital and Extra-hospital Nursing Care for Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The incidence of tuberculosis has decreased over the last 2 years on the national territory (6.4/100,000 inhabitants) but remains twice as high in Ile de France where it is increasing with an increase of almost 10% in the number of cases. reported between 2015 and 2017 . the notification rate of tuberculosis disease for the year 2020 was 14.3 cases per 100,000 inhabitants (i.e. 1757 cases declared) which is more than double that found at the national level . As the disease is multifocal, … |
EMMA TORRES; | 2025-08-26 |
| 41 | A Phase 1 Open-Label Human Vaccination and Challenge Study to Assess The Ability of Intradermal BCG TICE(R) Vaccination to Induce Protective TB Immunity Capable of Inhibiting Replication In Vivo in Healthy Human Volunteers Related Papers Related Patents Related Grants Related Experts Highlight: A nonrandomized, open-label trial will be conducted with a total of 64 healthy male and non-pregnant females, ages 18-45 years. Participants in Group A will enroll 32 participants to receive 2×10\^6 colony- forming units CFU TICE(R) BCG vaccination on Day 1 and 4×10\^6 CFU challenge on Day 181. Once enrollment has been completed in Group A, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2025-12-17 |
| 42 | Candidate Clinical Correlate of Prognostic Outcome for TB Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials. |
ADITHYA CATTAMANCHI; | 2026-01-23 |
| 43 | Clinical Efficacy of A Short-course Regimen for Asymptomatic Tuberculosis in China PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin. |
WEN-HONG ZHANG; | 2026-02-11 |
| 44 | A Phase I Randomized, Double-blind, Placebo-controlled and Dose Escalation Study to Evaluate The Safety and Immunogenicity of A Viral Vector-based Tuberculosis (TB) Vaccine Ad5-105K Against TB Disease in Adults Aged 18 to 49 Years PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant’s gender and age should be balanced in each group. |
ERLINA BURHAN; | 2025-12-11 |
| 45 | Definition of Sub-phenotypes of Pneumonia Based on The Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The PHENOMENON study aims to investigate the relationship between the respiratory microbiome composition and clinical outcomes to improve the prediction of treatment failure and AMR emergence. Methods: This multicenter prospective cohort study will include 300 adult patients across three cohorts: CAP in general wards, severe CAP in intensive care units (ICU), … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2025-11-24 |
| 46 | Effectiveness and Safety of Auricular Acupuncture for Nausea and Vomiting Side Effects Induced By Anti-Tuberculosis Drugs in Pulmonary TB Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will look at whether press-needle ear acupuncture can help lower nausea and vomiting caused by antituberculosis medicines in people with pulmonary tuberculosis. Nausea and vomiting are common side effects of tuberculosis treatment, and they can make people stop taking their medicines When treatment is stopped too early, … |
KEVIN SUPRATMAN; | 2025-12-09 |
| 47 | DoseTB-individualised Dosing By Model-informed Precision Dosing for Pulmonary Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to investigate whether model-informed precision dosing (MIPD), as a clinical support for early individualised dosing in addition to the national TB care program, can optimise the drug exposure of TB drugs during TB treatment. Main research questions: In adult patients with drug-susceptible pulmonary tuberculosis, can current dose recommendations and information received from MIPD help clinicians in a timely manner to optimise the drug exposure of TB drugs in the early treatment phase, i.e., … |
LINA DAVIES FORSMAN; | 2025-11-21 |
| 48 | Window Prophylaxis for Mycobacterium Tuberculosis Infection Prevention in Child and Adolescent Household Contacts: A Cluster-Randomized Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this cluster-randomized controlled trial is to evaluate the effectiveness of tuberculosis preventive treatment (TPT) administered during the window period to prevent new Mycobacterium tuberculosis infections in children and adolescents. The main question it aims to answer is: Can immediate TPT reduce the incidence of IGRA conversions in children and adolescents who are household contacts of a newly diagnosed pulmonary tuberculosis patient? Researchers will compare the incidence of new tuberculosis infections-measured by IGRA conversion at 12 weeks-between participants who receive immediate TPT while still uninfected (baseline IGRA-negative) and those who receive standard care, … |
MARÍA ELVIRA BALCELLS; | 2025-12-29 |
| 49 | A Multi-center Longitudinal Observation Translational Study to Evaluate Phenotypes, Endotypes and Biomarkers in Chinese Patients With NCFBE PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic respiratory disease characterized by a clinical syndrome of chronic productive cough and recurrent respiratory infections in the presence of abnormal and permanent dilation of the bronchi. Recent epidemiological studies have clearly shown that the prevalence and incidence of NCFBE are quickly rising both in high- and low-income countries. With the increase of prevalence, bronchiectasis brings huge medical and economic burden to the society. In this study, … |
JINFU XU; | 2026-03-30 |
| 50 | Preoperative Prediction of VATS Strategy in Parapneumonic Effusion PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Video-assisted thoracoscopic surgery (VATS) has revolutionised management of complicated parapneumonic effusion ( PPE). So our study is prospective cohort study will be conducted at Departments of Chest Diseases and Cardiothoracic Surgery, Assiut University Hospitals * Aims: to determine the frequency of which VATS technique is needed (decortication versus debridement ) and to verify whether baseline RAPID score and pleural US parameters can predict which VATS procedure (decortication vs. debridement) in patients with complicated PPE will need, … |
HAMED FARRAG QENAWY; | 2025-09-23 |
| 51 | A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate The Efficacy, Safety, and Tolerability of 4-month and 6-month Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB. The main goal is to see if a new drug called quabodepistat, when combined with other TB drugs, … |
OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION | 2026-02-10 |
| 52 | A Phase 2 Trial to Evaluate The Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Abstract: This is a single-centre, open-label, single arm, clinical trial in two sequential stages, with no stratification. 12 patients will be enrolled in Stage 1, and a further 12 … |
THIRTY RESPIRATORY | 2026-01-12 |
| 53 | Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: PRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). In Stage 1, participants will be randomized among one of three treatment arms (one control and two experimental). Following the interim analysis (at the end of Stage 1) based on DOOR outcome comparisons and the entirety of the data, one of the four possible experimental strategies will be identified and continue into Stage 2. In Stage 2, … |
GUSTAVO E VELÁSQUEZ; | 2026-01-20 |
| 54 | Investigation of Postural Parameters, Physical Functions, Balance and Quality of Life in Different Hip Pathologies PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: It is known that pelvic parameters affect physical hip functions in hip pathologies. Depending on the type and severity of hip pathologies, posture, muscle strength, balance, and pain parameters may change, thereby impacting an individual’s quality of life. This study aimed to examine the postural parameters, muscle strength, balance, quality of life, pain intensity, and pain localization of individuals with different hip pathologies, including hip osteoarthritis, hip impingement syndrome, hip labrum tear, hip dysplasia, and hip avascular necrosis. |
ESRA ATEŞ NUMANOĞLU; | 2025-12-18 |
| 55 | Precision Rifampin (P-RIF) Trial for Personalized Dosing in Active Tuberculosis Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Individual pharmacokinetic variability is an important driver of tuberculosis (TB) treatment failure particularly among undernourished populations, and that suboptimal serum drug concentrations are associated with delayed response to treatment, death, and acquired bacterial drug resistance. Serum drug exposures can be approximated by urine excretion as measured by spectrophotometry, replacing the need for specialized equipment for serum testing. Anti-TB pharmacokinetic variability has also been associated with enteric pathogen burden. The overall hypothesis is that urine spectrophotometry will identify people with below-target rifampin serum concentrations, which can be corrected to target levels after dose adjustment as confirmed by serum mass spectrometry. Therefore, … |
SCOTT HEYSELL; | 2026-01-27 |
| 56 | Study of The Prevalence and Patterns of Drug Resistance of Mycobacterium Tuberculosis Using GeneXpert (MTB/RIF) and Xpert (MTB/XDR) Assays PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is fundamental. Identifying the pattern of drug resistance will ensure that the most effective therapy can be selected. The aim of this study is to assess the prevalence and patterns of drug resistance of mycobacterium tuberculosis and to detect the possible risk factors associated with resistant cases. |
OMNIA ABDELAZIM MOHAMED; | 2025-09-11 |
| 57 | A Randomized Controlled Trial for Studying The Efficacy and Safety of Dexmedetomidine Vs Midazolam for Procedural Sedation During Medical Thoracoscopy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Medical thoracoscopy can be performed under procedural sedation (conscious sedation) in most of the cases. Procedural sedation is a state where the patient lies comfortably without much movement, does not feel pain and has a dissociative state (separation of mind and body. In view of the existing literature, we hypothesize that use of dexmedetomidine for procedural sedation during medical thoracoscopy will improve the ease of performing the procedure, lower the consumption of rescue analgesics and risk of intra- and post-procedure complications, improve the yield, … |
INDERPAUL SINGH; | 2026-03-18 |
| 58 | Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a diagnostic study. Patients and healthy volunteers with clinically suspected or confirmed colorectal cancer, gastric cancer, pancreatic cancer and other malignant tumors with high expression of GPA33 will be recruited for PET/MR or PET/CT imaging targeting a GPA33-specific probe (in the case of \[68Ga\]Ga-NOTA-GPA33 nanobody) , to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET imaging in patients with contraindications. General information on the subjects’ vital signs, clinical data, blood routine, … |
UNION HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY | 2025-09-15 |
| 59 | Safety and Efficacy of RAP-103 in Dose of 400mg/Day/One Dose A Day, 200mg/Day Twice Dose A Day, or Placebo Administrated for 8 Weeks, to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects 18y to 70y: Randomized, Double Blind, Phase 2, Proof of Concept, Placebo Controlled Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Randomized, controlled trial, Proof of Concept, Phase 2 aimed to evaluate the effect of RAP-103 in dose of 400mg/day/one dose a day, 200mg/day twice dose a day, or placebo administrated for 8 weeks to improve Psoriasis Area and Severity Index (PASI)75 or static Physician’s Global Assessment (sPGA) score of 0 or 1; PASI50, PASI90, PASI100, Scalp-specific Physician’s Global Assessment (Ss-PGA) 0/1 with at least a 2-point improvement among patients with a baseline ss-PGA ≥3, sPGA 0, PSSD symptom score of 0 among patients with baseline score ≥1, … |
VERONICA NARVAEZ ROSALES; | 2025-10-02 |
| 60 | A Study on The Short – Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin – Resistant/Multidrug – Resistant Pulmonary Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate. This is related to the large number of drugs in the RR-TB treatment regimen, the high incidence of adverse reactions, and the long treatment course, which lead to poor patient compliance. There is an urgent need for new, effective, safe, and short-course anti-drug-resistant regimens. A 6-month short-course oral regimen containing pretomanid was launched in 2020 and was approved for marketing in China in March 2025. Currently, … |
WUHAN PULMONARY HOSPITAL | 2025-09-25 |
| 61 | The Effect of Benson Relaxation Exercises on Sleep Quality in Patients With Lung Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to investigate the effect of Benson Relaxation Exercises on sleep quality in hospitalized patients diagnosed with lung cancer. It is planned to be conducted as a randomized controlled trial. Hypotheses of the Study H1: The sleep quality of lung cancer patients who undergo Benson relaxation exercises is statistically significantly better than that of patients who do not undergo such exercises. H2: There is no significant difference in sleep quality between patients who undergo Benson relaxation exercises and those who do not. |
ELÇIN BABAOĞLU; | 2025-10-08 |
| 62 | 6 Months of Bedaquiline, Delamanid, Linezolid and Levoffoxacin in RR-TB Patients in Hubei Province PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to compare the efficacy and safety of a 6-month all-oral regimen including Bedaquiline (BDQ,B), Delamanid (DLM,D), Linezolid (LZD, L), and Levofloxacin (LFX,L) to the the standard long – course treatment regimen within the Chinese population. The main questions it aims to answer are: Is the efficacy of short regimen non-inferior to standard regimen? Is the short regimen safe enough to replace the standard regimen? Participants will: Be given with either short or standard regimen for RR-TB treatment Be asked to complete the scheduled visit as planned. |
YAN HU; | 2025-09-30 |
| 63 | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis |
BRISTOL MYERS SQUIBB | 2026-04-02 |
| 64 | A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare The Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets With Delamanid in Patients With Rifampin-resistant Tuberculosis (JD-RISE) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks. |
WESTVAC BIOPHARMA | 2026-01-30 |
| 65 | Dolutegravir Plus Lamivudine (DTG/3TC) Dual Therapy Versus Dolutegravir With TDF-lamivudine (DTG + TDF/3TC) Among Antiretroviral Naïve People With HIV and TB Receiving Rifampin-based TB Treatment PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice daily or DTG/3TC ( Dovato) in the morning +dolutegravir (DTG) in the evening, versus standard of care (SOC) twice-daily dolutegravir plus 2 once-daily Nucleoside reverse-transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate /lamivudine (TDF/3TC), among antiretroviral therapy (ART)-nave individuals with HIV-1 receiving rifampin-based TB therapy |
ETHEL M WELD; | 2025-09-24 |
| 66 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Trial in Healthy Adult Participants to Evaluate The Safety, Tolerability, and Pharmacokinetics of TBD09 With An 84-day Period of Fixed Daily Dosing PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, double-blind, placebo-controlled, multiple dose trial of TBD09, administered to healthy adult participants to assess safety, tolerability, and pharmacokinetics up to 84 days of fixed daily dosing of TBD09. The trial will be conducted with two cohorts, with participants enrolled in parallel and randomized to receive either TBD09 or placebo. |
GATES MEDICAL RESEARCH INSTITUTE | 2026-01-22 |
| 67 | Artificial Intelligence-assisted Chest X-ray in TB Screening: Effectiveness of Enhancing The Care Cascades in Chinese Primary-care Settings (ACCESS-CARE) PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The global incidence rate and mortality of tuberculosis (TB) pose a challenge to achieving the goals set out in the tuberculosis eradication strategy and the SDGs by 2030. At present, timely and accessible early detection methods for tuberculosis are still a major obstacle. In this context, the emergence of artificial intelligence (AI), especially the AI-assisted chest X-ray (CXR) in the field of diagnostic imaging, has proved the potential to significantly improve the speed and accuracy of tuberculosis diagnosis. However, the extent to which these technologies can affect the broader tuberculosis care cascade, … |
XUELIN YANG; | 2025-12-31 |
| 68 | Testing New Diagnostic Technology Classes for TB (DriveDx4TB) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This prospective multicentre study is planned to evaluate the next generation LAM assays and molecular diagnostics (POC and near POC) among people with presumptive Tuberculosis. The DriveDx4TB study aims to generate evidence needed to accelerate the introduction of three new classes of TB diagnostics, complemented by alternative sampling for use at primary healthcare and community settings. To this end, the study will leverage the accelerated innovation spurred by the COVID-19 pandemic, particularly the rapid development of swab-based sampling and molecular diagnostic (MDx) platforms. |
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS SWITZERLAND | 2025-06-24 |
| 69 | Respiratory Health and Wellbeing Post Pulmonary Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: We know that in low-income countries where there is a lot of tuberculosis (TB) about 20%-50% of people treated for TB have long term problems with their lungs and general wellbeing. This means they can’t always get back to doing activities they were doing before they had TB and may need further treatment, for example antibiotics, inhalers or special rehabilitation classes. Some people are unnecessarily treated again for TB because they still have a cough. There have been two international guides published recently, describing standards for providing follow up care for people treated for TB. However, … |
LIVERPOOL SCHOOL OF TROPICAL MEDICINE | 2025-09-17 |
| 70 | Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if genistein works to provide a beneficial effect to show lipid lowering effect and anti-inflammatory effects and slow the progression of atherosclerosis in post-myocardial infarction adults. It will also learn about the safety of genistein. The main questions it aims to answer are: Does genistein lower triglyceride in participants? What medical problems do participants have when taking genistein? Researchers will compare the baseline, under treatment and washout period triglyceride, … |
NATIONAL TAIWAN UNIVERSITY HOSPITAL | 2025-08-07 |
| 71 | The Effect of Su Jok Application on Pain, Anxiety and Comfort Levels After Cesarean Section PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Objective: To determine the effect of Su Jok application on pain, anxiety and comfort level after cesarean section. The research will be conducted as a randomized controlled experimental study with pretest-posttest control group |
AYSE AYDIN; | 2025-07-29 |
| 72 | DIRECT: Doxycycline Adjunctive Therapy to Reduce Excess Mortality and Complications From Central Nervous System Tuberculosis – Phase II Randomized Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Although tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary hospital centers. At present, the SOC for the management of CNS-TB is anti-tuberculous therapy with adjunctive corticosteroids. In CNS-TB, the activity of pathogenic host matrix metalloproteinases (MMPs) is unopposed to tissue inhibitors of metalloproteinases (TIMPs), resulting in a matrix-degrading phenotype which may drive worse outcomes in CNS-TB. In a prior established CNS-TB murine model, the investigators have demonstrated that adjunctive MMP inhibition using doxycycline, a widely available and cheap drug, … |
NATIONAL UNIVERSITY HOSPITAL SINGAPORE | 2025-08-27 |
| 73 | Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: # Brief Summary This study aims to evaluate the early bactericidal activity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible tuberculosis. This is a prospective, randomized, controlled, multicenter study planned to enroll 45 rifampicin-susceptible tuberculosis patients, who will be randomized in a 1:1:1 ratio to the BZMD group (bedaquiline + pyrazinamide + moxifloxacin + delamanid), BZMH group (bedaquiline + pyrazinamide + moxifloxacin + isoniazid), and standard control group. Subjects in the test groups will receive 17 weeks (4 months) of group-specific treatment regimens, … |
WEI SHA MD & PHD; | 2025-08-19 |
| 74 | End-to-end Digital Transformation for Primary Health Care Performance Management Via Scalable Public Health Empowerment, Research, and Education Sites: A Stepped-Wedge Cluster Randomized Trial PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: SPHERES is a health service research trial in the Indonesian primary care system designed to improve health system performance using a structured data-driven action model. The intervention empowers district health leaders to make data-informed decisions that will enhance outcomes across maternal, child, infectious, and non-communicable disease programs. |
ANURAJ SHANKAR; | 2025-08-15 |
| 75 | An Observational Cross-sectional Study Exploring Differences in Health Between People With Non-Tuberculous Mycobacteria Pulmonary Disease and People With Bronchiectasis Without NTM Pulmonary Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis. The number of people with NTM pulmonary disease (PD) is increasing, and its management can be complex, requiring prolonged treatment with multiple, often toxic, drugs in someone who may already be frail. Non-drug approaches, such as airway clearance techniques, structured exercise, … |
MARC LIPMAN; | 2025-09-25 |
| 76 | Questioning The Epidemiology of Asymptomatic TB PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) remains one of the world’s leading causes of morbidity and mortality. Current TB control strategies focus largely on the binary paradigm of TB, which tackle Mtb infection and the symptomatic stages of the disease as the major drivers of the TB epidemic. However, prevalence surveys have shown that about 50% of cases in which Mycobacterium tuberculosis is isolated from sputum but do not report having symptoms. Therefore, asymptomatic TB may play an important role in TB transmission. However, … |
ALBERTO GARCIA-BASTEIRO; | 2025-12-31 |
| 77 | Phase III Clinical Trial to Evaluate The Efficacy and Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) for The Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a randomized, blinded, active-controlled clinical trial to evaluate the effectiveness and safety of EEC in the diagnosis of Mycobacterium tuberculosis infection in people aged 3 years and above. Methods: In study 1, the marketed recombinant Mycobacterium tuberculosis fusion protein (EC) was used as a control drug in people aged 3 to 64 years. The sensitivity of EEC in participants with tuberculosis and the specificity in healthy participants and patients with non-tuberculous lung diseases were evaluated compared with recombinant Mycobacterium tuberculosis fusion protein (EC). The clinical positivity criteria of EEC were verified, … |
PEI YI; | 2025-09-03 |
| 78 | An Open-label, Randomized Controlled Trial of The New One-month Regimen Versus The Current Three-month Regimen for The Treatment of Tuberculosis Infection in Vietnam PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Introduction: Tuberculosis (TB) infection is a key driver of the TB pandemic, with over 10.6 million people fell ill with TB disease in 2022. About one-quarter of the global population is estimated to be infected with TB bacteria. Around 5-10% of people with TB infection will develop active and contagious TB disease, which could be largely avoided if TB infection is identified and given effective preventative treatment, … |
LUONG VAN DINH; | 2025-03-19 |
| 79 | Effects of Adjunct Omega-3 Long-chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patients: An Early Bactericidal Activity and Inflammatory Activity Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients (aged 18- 45 years) with newly diagnosed, … |
LINDA MALAN; | 2025-08-12 |
| 80 | Paediatric Post-TB Home-based Pulmonary Rehabilitation Feasibility Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if a home-based pulmonary rehabilitation program is feasible and acceptable for children ages 6-15 who have recently completed treatment for pulmonary tuberculosis. The main questions it aims to answer are: Can children and caregivers follow a 6-week rehabilitation program? Is the program acceptable and feasible for children and caregivers? Researchers will also explore preliminary changes in walking distance and quality of life. Participants will: Attend a clinic visit for baseline testing, … |
GRETA L. BECKER; | 2025-08-11 |
| 81 | Investigation on The Prevalence and Etiology of Adolescent Idiopathic Scoliosis in Nanchang Region PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the prevalence and etiology of adolescent idiopathic scoliosis in the Nanchang region. Elementary and middle school students who met the inclusion criteria were included in the study and school-based scoliosis screening was conducted. Diagnosis of suspected scoliosis was determined by physical examination, Adams forward bend test, measurement of trunk rotation angle, and Standing Anteroposterior X-ray of the Spine. The prevalence of suspected scoliosis among elementary and middle school students was calculated. At the same time, the researchers kept detailed records of all costs incurred in the school screening. |
WENTAO ZENG; | 2025-05-30 |
| 82 | A Ultrashort Regimen for Drug-susceptible Pulmonary Tuberculosis in Elderly Patients: A Multicenter Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) remains one of the leading global public health concerns and is among the top ten causes of death from a single infectious agent. China ranks third worldwide in total TB burden, with a substantial proportion of cases classified as drug-susceptible TB (DS-TB). Despite the availability of effective standard treatment regimens, the current 6-month therapy duration poses challenges in terms of patient adherence, resource allocation, and overall treatment success. In recent years, ultrashort-course regimens for DS-TB have been proposed and evaluated in clinical studies, showing promising results in improving adherence, reducing treatment duration, … |
SHUIHUA LU; | 2025-07-22 |
| 83 | Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases. |
REGENERON PHARMACEUTICALS | 2025-10-10 |
| 84 | Evaluation of 200 Mg of Rituximab Every 6 Months As Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis: A Non-inferiority Prospective Randomised Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting joints and causing progressive disability. Current treatment strategies involve conventional disease-modifying anti-rheumatic drugs (csDMARDs) and, in more resistant cases, biologic DMARDs (bDMARDs) such as Rituximab. Rituximab, a monoclonal antibody targeting CD20-positive B cells, is administered as an induction dose followed by maintenance therapy every six months. Standard maintenance dosing consists of 1g infusions, but lower doses may provide equivalent efficacy with fewer side effects. The RADAR trial is a multicenter, prospective, randomized, double-blinded, … |
UNIVERSITY HOSPITAL STRASBOURG FRANCE | 2025-07-23 |
| 85 | Shape-sensing Robotic-assisted Bronchoscopy (ssRAB) for Diagnosis of Peripheral Pulmonary Nodules: A Prospective Cohort Study in Korea (the ULSAN-ION Study) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: What is this study about? This study tests a new robotic technology to take tissue samples from lung nodules (small spots in the lungs). Some lung nodules are cancer, but doctors need a tissue sample to know for sure. What is the problem? Current methods to get tissue from lung nodules only work about 7 out of 10 times. When they don’t work, … |
GANGHEE CHAE; | 2026-02-13 |
| 86 | Unravelling The Measles Paradox: A Disease Associated With Both Immune Suppression and Immune Activation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The measles (MeV) paradox refers to an apparent contradiction: natural measles causes a transient but profound immune suppression putting patients at risk for opportunistic infections for years, while at the same time MeV infection induces robust immune activation leading to lifelong protection against measles. In this protocol, we test our hypothesis that natural measles causes immune amnesia by altering the composition of circulating immune memory cells. In comparison to the prior studies performed during the 2013 outbreak, we will specifically determine \[1\] to what extent pre-existing immunity is reduced, \[2\] for how long this functional immune suppression can be detected, … |
CORINE GEURTS VAN KESSEL; | 2025-12-05 |
| 87 | Epidemiological Survey and Follow-up of Cardiovascular-Kidney-Metabolic Diseases Among Adults in Shanghai PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants. The study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, … |
TUO LI; | 2025-09-08 |
| 88 | Confocal Laser Endomicroscopy Combined With Rapid On-Site Cytological Evaluation for The Diagnosis of Intrathoracic Lymphadenopathy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to describe and validate confocal laser endomicroscopy(CLE) and rapid on-site evaluation(ROSE) interpretation criteria for different types of intrathoracic lymphadenopathy. |
JIAYUAN SUN; | 2025-07-02 |
| 89 | Digitally Facilitated, Integrated Community and Facility-Based Interventions to Improve Tuberculosis Case Detection and Treatment Adherence in South Ethiopia: A Type II Hybrid Effectiveness-Implementation Study: The HEART-TB Trial Protocol PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Effective tuberculosis treatment outcome relies on adherence. However, many TB patients struggle to adequately adhere to their prescribed regimen due to various social, economic, personal, and healthcare system barriers. However, previous interventions did not adequately consider combined strategies in a way that addressed social, personal, economic, and health system barriers to case detection, treatment adherence, and outcomes. As a result, the investigator developed novel holistic interventions, which include community-based TB patient support, family and patient adherence support strategies, digital adherence support strategies, … |
MULUGETA DALBO DATAMO; | 2026-02-27 |
| 90 | Comparison of The Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at A Tertiary Care Hospital , Karachi PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: OBJECTIVE : To compare the outcome of treatment with silymarin or N-acetyl cysteine in patients taking anti-tuberculous drugs for tuberculosis at Tertiary Care Hospital, Karachi. SAMPLE SELECTION : Patients presenting with tuberculosis previously not on anti-tuberculous drugs, between 40-80 years of age, both genders will be included .Patients with history of alcohol use,Discontinuation of drug due to other adverse effects except hepatotoxicity ,Inadequate date of laboratory testing at baseline or 2 to 4 weeks after treatment initiation, Cases with human immunodeficiency virus (HIV) co-infection, viral hepatitis, or suspected mal absorption (e.g., gastrointestinal disease or diarrhea) ,Chronic liver disease, COPD, asthma, … |
ARIBA SULTAN; | 2025-07-10 |
| 91 | Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures. This is highlighted by the emergence of mutations encoding resistance to bed aquiline and quinolones which may impact the roll out of the newly recommended Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (BPaLM) regimens. It is also worth noting that there is increasing evidence of the significance of TB lineage in the outcome of infection, the approach in the study will provide both information on chains of transmission and lineage. |
CENTRE DE RECHERCHE MÉDICALE DE LAMBARÉNÉ | 2025-06-12 |
| 92 | A Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the highest TB burden, ranking third globally for total TB cases and second for drug-resistant TB cases. PAN-TB is an innovative concept in TB treatment, aiming to develop a universal regimen effective for all forms of active TB, including both drug-susceptible and drug-resistant strains. The primary goal of the PAN-TB regimen is to simplify the treatment process, reduce costs, … |
SHUIHUA LU; | 2025-12-01 |
| 93 | SSTARLET: Shorter and Safer Treatment Regimens for Latent TB PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Our study rationale is based on: 1. Tuberculosis Preventive Treatment (TPT) is given to healthy people and needs to be safe; 2. Tuberculosis Preventive Treatment (TPT) with shorter regimens are superior with respect to acceptance, completion, and costs; 3. 4 months of Rifampin 10mg/kg (4R10) is the safest regimen, but is completed by \<80% of patients; 4. The safety of 2 months of Rifampin 20mg/kg (2R20) is similar to that of 4 months of Rifampin 10mg/kg (4R10), but completion is a concern; 5. 1-month regimens have promising efficacy; ... |
DICK MENZIES; | 2026-02-10 |
| 94 | Novel Pleural Effusion Biomarkers Screening and Evaluation in Lung Adenocarcinoma Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma. |
KE-YUN CHAO; | 2026-03-05 |
| 95 | Biomarker-guided Diagnosis of Tuberculosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to identify new biomarkers that enable reliable, non-invasive diagnosis of tuberculosis (TB), including in patients who are unable to produce sputum. The study analyzes biomaterials (blood, urine, stool, sputum) collected from patients with suspected TB. Various diagnostic methods are applied to assess the feasibility of individual and combined biomarker tests. Participating patients will provide biomaterial samples (blood, urine, stool, sputum) once. No additional examinations or invasive procedures will be performed. Routine diagnostic procedures remain unaffected. This is a single-center, … |
THOMAS THEO BREHM; | 2025-08-15 |
| 96 | Developing, Implementing and Evaluating of Self-management Behavior Intervention Through Shared Medical Appointment for COPD Patients (SMA-COPD): A Multi-stage Mixed Methods Research PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate whether a behavior change intervention, delivered through a shared medical appointment (SMA) model, can improve self-management behaviors and health outcomes among community-based patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are: i) Can a BCW-based intervention strategy that integrates shared medical appointments increase COPD patients’ self-management behaviors? ii) Does this strategy relate to reduced acute exacerbations, slower lung function decline, … |
PEKING UNIVERSITY THIRD HOSPITAL | 2025-08-19 |
| 97 | Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France – ANRS 464s FrenchTB PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The French Tuberculosis Cohort is a prospective, national, multicenter, low-intervention study including subjects aged 18 years and older with tuberculosis disease for which inpatient treatment is initiated. The goal of this observational study is to follow-up and anti-tuberculosis treatment will be provided according to current French recommendations. Participants will provide sociodemographic, clinical, biological, radiological and bacteriological data at various protocol visits at 2 days, 1 and 2 weeks, 2 months, at the end of treatment, 12 and 24 months. Consenting participants will have samples collected at scheduled visits for the establishment of a biobank. This will include blood, urine, … |
NATHALIE DE CASTRO; | 2025-03-25 |
| 98 | Closing The Tuberculosis Diagnosis Gap in Rural and Malnourished Populations PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Tuberculosis (TB) remains a large public health threat in Tanzania with an estimated incidence of 195 per 100,000 people in 2022 and 36% of cases going undiagnosed. Nutritional and financial barriers combine to compound the burden of TB in Tanzania and many other high burden countries. Objectives: In this study, we aim to evaluate the effect and cost-effectiveness of conditional cash transfer added to the current facility-based approach to improve TB screening among household contacts (HHCs) of index people diagnosed with TB disease (PWTB) in rural Tanzania; … |
GHASSAN ILAIWY; | 2025-05-14 |
| 99 | PRecision BiomArker-Guided MAnagement of TuberculosIs Contacts: A Discrete Choice Experiment PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is part of a broader programme of work to develop and pilot a randomised-controlled trial of new tests to identify people who will benefit most from preventive treatment for tuberculosis (TB). The aim of the current study is to explore factors affecting patient decisions to start preventive treatment. The specific objectives are to understand how patients make decisions about preventive treatment initiation for TB (stage 1); and to design and conduct a discrete choice experiment survey to further evaluate preferences (stage 2). |
MAHDAD NOURSADEGHI; | 2025-06-17 |
| 100 | BCG2-DTP3: Providing BCG Revaccination With The Third Dose of Diphtheria-tetanus-pertussis Vaccine to Improve Female Survival in Africa PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Studies in low-income countries show that vaccines can have important non-specific effects on other infections. Live BCG vaccine can train the immune system and reduce susceptibility to unrelated infections. In contrast, non-live diphtheria-tetanus-pertussis-containing (DTP) vaccine enhances susceptibility in females: DTP vs no DTP is associated with 2-fold higher mortality, and in DTP-vaccinated children, … |
CHRISTINE STABELL BENN; | 2025-06-12 |
| 101 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate The Safety and Explore The Immunogenicity of The Tuberculosis (TB) Vaccine Candidate QTP101 (ID93+GLA-SE) in Older Adults (Aged 55~74 Years) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, … |
JAE CHOL CHOI; | 2025-06-17 |
| 102 | Proton Therapy Versus Photon Therapy for The Treatment of Nasopharyngeal Carcinoma: A Prospective, Open-Label, Multicenter, Phase III Non-Inferiority Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, open-label, multicenter, cohort, phase III non-inferiority clinical trial comparing proton therapy with photon radiotherapy for nasopharyngeal carcinoma. It intends to enroll histologically confirmed newly diagnosed nasopharyngeal carcinoma patients without distant metastasis (M0). Through a prospective 1:1 matched cohort study design, patients will be divided into the intensity-modulated proton therapy (IMPT) group and the intensity-modulated radiation therapy (IMRT) group. Systemic treatment regimens are formulated according to clinical guidelines. |
MAN HU; | 2025-06-03 |
| 103 | A Confirmatory Trial of Adjunctive N-acetylcysteine to Prevent Post Tuberculosis Lung Disease (NAC-PTLD) – A TB SEQUEL II Substudy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate if N-acetylcysteine (NAC) works to prevent post-tuberculosis lung disease (PTLD) in patients with severe pulmonary impairment. It also aims to assess the safety of NAC. The main questions the study aims to answer are: Does NAC improve lung function (FEV1%) over 12 months in participants with pulmonary tuberculosis and baseline risk factors for PTLD? What medical issues or adverse events do participants experience while taking NAC? Researchers will compare NAC treatment to a control group to see if it can prevent PTLD when given in addition to standard TB treatment. Participants will: Take NAC (1800mg twice daily) for 6 months with standard TB treatment or receive standard TB treatment alone; Attend scheduled clinic visits for 12 months, during which they will have respiratory assessments, blood tests, and symptom monitoring; Complete quality-of-life questionnaires and provide sputum and blood samples for analysis at multiple time points. |
ROBERT WALLIS – PROFESSOR; | 2025-04-30 |
| 104 | REACH – Responsive Evaluation and Assessment for Communicable Diseases in Migrants Hosted in Reception Centers PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A single-centre, non-profit experimental clinical trial. The aim of the study is to estimate the prevalence of a range of infections and infectious diseases in a cohort of asylum seekers staying in initial reception centres, who have been in Italy for at least 2 months but no more than 36 months. The infections of interest are: latent tuberculosis and active tuberculosis, HIV, HBV, HCV, syphilis, strongyloidiasis, schistosomiasis, filariasis, and intestinal helminthiasis. |
IRCCS SACRO CUORE DON CALABRIA DI NEGRAR | 2026-03-30 |
| 105 | Comprehensive Digital Adherence and Remote Engagement to Optimise Treatment Adherence for Tuberculosis Patients (CARE-TB Study) in Selangor, Malaysia: An Effectiveness-Implementation Science Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The gold standard for tuberculosis (TB) treatment support requires directly observed therapy (DOT), which means a trained health worker observes the patient swallow each dose of medication every day for 2 months. Despite the practice of DOT in Malaysia, 1 in 20 patients are loss-to-follow-up and non-adherent to treatment. Sub-optimal adherence due to poor treatment acceptability and social desirability promotes TB treatment failure, disease relapse, on-going transmission, drug resistance, and death. Telemedicine offers a flexible and less invasive option to support TB treatment adherence. Despite 97% internet and smartphone penetration rates, … |
REENA RAJASURIAR; | 2025-07-16 |
| 106 | A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS) |
UCB BIOPHARMA SRL | 2026-03-27 |
| 107 | Rifapentine- And Moxifloxacin-Containing Short-Course Regimens for Mild Spinal Tuberculosis: A Multicenter, Randomized, Non-inferiority Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and pyrazinamide remaining the same as the empirical regimen) and the empirical long-course regimen, so as to determine whether it is possible to shorten the treatment duration to 26 weeks for patients with mild spinal tuberculosis. |
WEI ZHAO; | 2025-04-08 |
| 108 | ToolCAP: Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The ToolCAP study aims to see if using ultrasound to look at the lungs when children have symptoms of a lung infection will safely allow doctors to improve how they treat those infections. The study will also look at if it’s possible to improve how doctors decide which children need antibiotics. * Lung infections are the most common reason for children to go to the clinic/hospital. * Doctors usually give an antibiotic to every child with a lung infection. * Lung infections can be caused by 2 different types of germs – … |
PAPA MOCTAR FAYE; | 2025-06-18 |
| 109 | Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA (MTB CfDNA) in Tuberculous and Non-tuberculous Pleural Effusion PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is one of the major global health threats and is the second leading infectious cause of death after COVID-19 in 2022. Extrapulmonary TB (EPTB), amongst which tuberculous pleuritis (TBP) is one of the most common subtypes, poses additional obstacles to global TB control due to its difficulty in diagnosis. The diagnosis of TBP is challenging. The ideal way of confirming TBP is by direct detection of TB bacteria or its specific component in the pleural space. However, the performance of available diagnostic tests is far from satisfactory, and no single test can achieve multiple diagnostic goals simultaneously, … |
KA PANG CHAN; | 2026-03-31 |
| 110 | The Use of A Novel ESAT6/CFP10 Skin Test in Diagnosis of Latent Tuberculosis Infection Among Rheumatologic Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of the study is to pilot the application of a novel ESAT6/CFP10 (C-TST) skin test in rheumatologic disease patients prior to initiation of treatment with biologic and/or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD). This is a prospective observational study involving the recruitment of patients with rheumatologic diseases who are planned for initiation of b/tsDMARD. Eligible patients would undergo skin testing by the Mantoux technique with purified protein derivative (PPD) RT23 on one forearm and C-TST on the other, … |
SHUI-SHAN LEE; | 2025-09-10 |
| 111 | Understanding Psycho-socioeconomic Linkages Through An Intervention Providing Enhanced Financial and Social Support During Tuberculosis Treatment PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Introduction: Tuberculosis (TB) remains an ongoing public health and socioeconomic challenge worldwide, especially in low- and middle-income countries such as Vietnam. Despite improvements in healthcare, TB still causes significant problems to those infected, especially within marginalized populations, including financial hardship, stigma, and mental health issues. This study aims to assess the effectiveness of a psycho-socioeconomic support intervention intended to improve treatment outcomes and reduce financial hardship faced by TB-affected households in Vietnam, … |
RACHEL FORSE; | 2025-04-08 |
| 112 | A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for The Treatment of Pulmonary Tuberculosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) measurements over the first 6 weeks of treatment, and will have acceptable safety and tolerability over 8 weeks of treatment relative to standard of care \[(SOC) isoniazid/rifampicin/pyrazinamide/ethambutol (HRZE)\]. The study will run for 52 weeks, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-03-19 |
| 113 | Open-Label, Single-Arm Trial to Evaluate The Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration. |
UCB BIOPHARMA SRL | 2026-02-27 |
| 114 | A Phase 2 Randomized, Open-label Trial to Evaluate The Early Bactericidal Activity, Safety, Tolerability, and Dose-Response of Oral Alpibectir in Combination with Ethionamide, and with Ethionamide, Rifampicin, Pyrazinamide, and Ethambutol in Adults with Newly Diagnosed, Drug-Susceptible Pulmonary Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A multi-centre, randomized, open-label clinical trial. All treatments will be administered orally (PO) on days 1-14. 15 participants will be recruited into each treatment arm in two sequential cohorts. Each cohort will have participants enrolled onto the experimental regimen(s) or the standard of care (SOC; HRZE) control arm. • Cohort 1 aims to generate safety data for a higher dose of alpibectir plus ethionamide 125 mg and 250 mg (arm 1: A45E125 and arm2: A45E250). Once 5 participants have enrolled into arms 1 and 2 each, and completed 14 days of treatment, … |
GIFTY OKYERE-MANU; | 2025-03-07 |
| 115 | Start Taking Action For TB Diagnosis (START4ALL) PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: Globally, tuberculosis (TB) is one of the main causes of death and the leading cause from a single infectious agent. In 2020, an estimated 9.9 million people developed TB and 1.5 million died. Millions of people remain undiagnosed with TB, hindering efforts to end TB. TB tests have inadequate accuracy or performance characteristics for implementation across all populations and settings. None of the tests meet the WHO-Target-Product Profile for TB screening and most need specialized laboratory staff and infrastructure, … |
LIVERPOOL SCHOOL OF TROPICAL MEDICINE | 2025-11-21 |
| 116 | Evaluation of The Therapeutic Effects of Mechanically Engineered Umbilical Cord-Derived Stem Cell Exosomes on Endometrial Injury: A Prospective, Non-Randomized, Parallel-Controlled Clinical Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate if engineered mechanically umbilical cord-derived stem cell exosomes, or conventional umbilical cord -derived stem cell exosomes, can improve endometrial thickness in women with thin endometrium. The main questions it aims to answer are: Can exosomes delivered via subendometrial injection improve endometrial thickness or clinical pregnancy rates compared to PRP (platelet-rich plasma)? Are there significant differences in endometrial thickness between the two treatment groups? Researchers will compare the intervention groups, which one group receives mechanical exosomes and the other receives conventional esosomes via subendometrial injection, to the control group, … |
TANG DU HOSPITAL | 2025-03-26 |
| 117 | A Phase 2b, Double-blind, Randomized, Placebo-controlled Study to Evaluate The Efficacy, Safety and Immunogenicity of A Candidate Tuberculosis (TB) Vaccine, MTBVAC, Against TB Disease in Adolescents and Adults Aged 14-45 Years, Living in A TB Endemic Region PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region. |
INTERNATIONAL AIDS VACCINE INITIATIVE | 2026-03-31 |
| 118 | Peripheral Blood Single Cell-type Expression Profile of Interferon-stimulated and Other Biomarker Genes for Triage of Febrile Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Febrile illness is a common condition and it is crucial to have an early triage of patients according to various aetiologies to enable appropriate treatment. Currently, most screening/diagnostic tests target the detection of pathogens, while only a few assays aim to understand the host response, and they are mostly based on a measurement of serum proteins (e.g. CRP or procalcitonin). Recently, blood transcriptome has been explored to differentiate bacterial and viral infections. However, gene expression in blood represents a composite score of gene expression of all the component cell-types present in the sample. Here, … |
NELSON TANG; | 2025-03-03 |
| 119 | Phase III, Open-label, Randomized, Multicenter Trial EvaLuating The Non-inferiority of DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection. |
PIERRE SELLIER; | 2026-01-07 |
| 120 | A Comparative Analysis of MGAP and GAP Trauma Scores in Predicting Prognosis for Multiple Trauma Patients: A Prospective Observational Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this prospective cohort study is to compare the predictive accuracy of the MGAP and GAP trauma scores in determining the prognosis of multiple trauma patients admitted to the emergency department at Al-Kadhimiya Teaching Hospital, Iraq. The main questions it aims to answer are: Does the MGAP score provide a more accurate prediction of outcomes compared to the GAP score? Are there specific subgroups of trauma patients where one score demonstrates superior predictive utility over the other? Participants will: Be assessed using both the MGAP and GAP scores upon admission to the emergency department. Have their clinical outcomes, … |
ABDULILLAH R. KHAMEES; | 2026-03-04 |
| 121 | Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Erythroderma is a rare and severe dermatological manifestation of a variety of diseases. The most common form of erythroderma is erythrodermic psoriasis (EP), which accounts for 1-2.25% of all psoriatic patients, … |
MARIA IQBAL; | 2025-05-30 |
| 122 | Outcomes of Vitrectomy Versus Suprachoroidal Steroid Injection in Cases of Presumed-trematode Induced Granulomatous Intermediate Uveitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Presumed trematode-induced granulomatous intermediate uveitis (PTIGIU) presents with vitritis and complicated cataract (active stage) which, if left untreated, progresses to tractional retinal detachment (TRD) from the vitreoretinal traction (cicatricial stage) and eventually cilliary body shut down and atrophia bulbi Accordingly, timely diagnosis of such patients during the active stage is essential for early proper management to avoid complications that might eventually result in blindness. Many treatment modalities for the treatment of AC granulomas were reported, including various combinations of topical corticosteroids, systemic antiparasitic treatment, … |
MAHMOUD EKRAM MOHAMED RABIE; | 2025-08-05 |
| 123 | Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Acute liver failure (ALF) is a serious condition in which the liver suddenly stops working, often leading to life-threatening complications. While N-Acetylcysteine (NAC) is widely used to treat ALF caused by acetaminophen overdose, its benefits in ALF due to other causes, such as viral infections or drug reactions, remain uncertain. This study is a randomized controlled trial designed to investigate whether NAC can improve survival rates and reduce hospital stays in patients with non-acetaminophen-induced ALF. Participants will be randomly assigned to receive either NAC along with standard supportive care or standard supportive care alone. The study will measure survival rates, … |
MUHAMMAD IRFAN JAMIL; | 2025-03-12 |
| 124 | Intestinal Microbiota Transplant As A Strategy to Enhance The Resilience Capacity of The Elderly Aiming to Retain Muscular, Cognitive, and Metabolic Functions in A Stressful Environment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Sarcopenia, characterized by the progressive loss of muscle mass and strength in older adults, is a key factor in health deterioration. It affects 15% of people between 65 and 80 years old and over 50% of those over 80, compromising autonomy and increasing the risk of diseases. Sarcopenia not only impacts muscle function but also bone health, mobility, and is associated with cardiometabolic diseases and cognitive decline. It has been proposed that changes in the gut microbiota in aging individuals, known as gut dysbiosis, contribute to sarcopenia. Species diversity decreases, and bacterial representation is altered, … |
GONZALO JORQUERA; | 2026-01-21 |
| 125 | The Effect of Breathing Exercise Education and Follow-Up Supported By Tele-Nursing on Dyspnea and Quality of Life in Patients With Tuberculosis: A Single-Group Experimental Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study was conducted as a single-group, pretest-posttest quasi-experimental design. The sample consisted of 54 tuberculosis patients registered at a Tuberculosis Dispensary who met the inclusion criteria and agreed to participate. Data collection tools included the Patient Identification Form, Dyspnea-12 TR Scale, Multidimensional Quality of Life Scale (MILQ), London Chest Activities of Daily Living Scale (LCADL), Tele-Nursing Follow-up Form, and Tele-Nursing Evaluation Form. Descriptive statistics, paired sample t-test, and Wilcoxon Signed-Rank Test were used for data analysis. The intervention group received structured respiratory exercises training, including abdominal breathing, pursed-lip breathing, and effective coughing, … |
CANAN GÜNGÖR; | 2025-07-16 |
| 126 | Pediatric Optimal Tuberculosis Treatment Evaluation and Reassessment PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The treatment of tuberculosis disease in children benefits from clear and up-to-date recommendations from the World Health organization. The research issues supported by the WHO mainly concern tuberculosis treatment implementation in areas of high incidence and low economic level. Pediatric cohorts in countries with high economic levels are rare, making it impossible to quantify and describe deviations from optimal recommendations. The French recommendations are mainly focused on screening cases of tuberculosis, … |
HOSPICES CIVILS DE LYON | 2026-01-22 |
| 127 | Validation of The Kinshasa Lung Ultrasound Approach for The Narrowing of Differential Diagnosis in Children Admitted With Acute Respiratory Symptoms in Low-resource Settings PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Study team will perform a prospective, observational study in two sites in the Democratic Republic of Congo (DRC) and Bangladesh in children aged 3 months to 14 years, admitted to hospital with acute respiratory symptoms. The Kinshasa lung ultrasound (K-LUS) approach integrates existing WHO clinical guidelines, lung ultrasound diagnostic accuracy evidence and paediatric ultrasound guidelines. The approach was built using a modified Delphi technique and integrates six LUS profiles, two clinical history features (timing of onset, trauma) and one clinical examination feature (fever) to suggest one among 10 clinical diagnosis. After the initial diagnosis is established by the treating physician, … |
LUIGI PISANI; | 2025-02-21 |
| 128 | Effect of Cırcadıan Feedıng on Growth Parameters of Preterm Newborn PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study was planned as a randomized controlled experimental study to determine the effect of circadian feeding on the growth parameters of preterm newborns. The data of the study were collected from patients aged 32-34 in the Neonatal Intensive Care Unit (NICU) of Selçuk University Faculty of Medicine. It will consist of premature babies and mothers born during the first week of gestation. The sample size was planned to include 48 preterm newborns and their mothers. Mother-Preterm Introductory Information Form, Breast Milk Feeding Follow-up Form, Breast Milk Content Parameters Follow-up Form, Newborn Baby Follow-up Form, … |
AYSE SONAY TURKMEN; | 2025-03-04 |
| 129 | Rab 32 Gene Polymorphisms As A Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling. |
LYDIA ATEF NASSIEF; | 2025-02-11 |
| 130 | A Clinical Trial Evaluating The Safety of An Aerosol BCG Controlled Human Infection Model in Assessing The Immunogenicity of Historical BCG Vaccination and Vaccination With ID93/GLA-SE in Healthy Adult Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2. Provide preliminary immunogenicity data of this novel TB vaccine (ID93/GLA-SE). This clinical trial will apply an aerosol BCG challenge model involving 48 participants – 24 historically BCG-vaccinated volunteers and 24 BCG-naïve volunteers. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity. |
HELEN MCSHANE; | 2025-12-12 |
| 131 | The Potential Development of I-FALMIN As A Phytopharmaca Candidate for Albumin Supplementation Derived From Toman Fish in Patients With Pulmonary Tuberculosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the potential of I-FALMIN, a supplement derived from toman fish (Channa micropeltes), as an additional source of albumin in patients with pulmonary tuberculosis. Tuberculosis patients often experience low albumin levels, which may slow down recovery. The purpose of this study is to determine whether giving I-FALMIN as a supplement, in addition to standard tuberculosis treatment, can improve albumin levels and support overall health status. The study will compare outcomes between patients who receive I-FALMIN and those who do not. |
MUH. NASRUM MASSI; | 2025-09-22 |
| 132 | Role of BARriers in IgG-Pathogen Interactions at The Mucosal Surface in Human Airways PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Context. Non cystic fibrosis bronchiectasis (NCFB) is a group of suppurative chronic airway diseases of multiple causes. Bronchiectasis is characterized by an abnormal, irreversible dilatation of the bronchi, airway obstruction, chronic cough, and sputum production. Inhaled polyclonal immunoglobulin G (IgG) is a new therapeutic approach for NCFB. Inhaled IgG is expected to have beneficial effects due to its ability to reduce the range of respiratory pathogens capable of infecting the respiratory tract, decrease the pulmonary load of existing bacterial populations, improve mucociliary clearance by restoring epithelial cell functions, … |
LAURENT PLANTIER; | 2025-12-10 |
| 133 | Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease, including 0.3 million people with human immunodeficiency virus (HIV) infection . TB remains the primary killer of HIV-positive individuals. TB incidence is falling at about 2% per year . Airborne transmission of M. tuberculosis typically causes TB infection in both immunocompetent and immunocompromised hosts and the disease is symptomatic and contagious . |
NOHA SABER SHAFIK; | 2025-06-01 |
| 134 | Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline in A Double Blind Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to assess the efficacy(effectiveness) of doxycycline, a potent inhibitor of matrix metalloproteinase (lung collagenase) activity in prevention of Tuberculosis associated lung fibrosis and associated lung function decline among patients with drug sensitive advanced TB. The main question\[s\] it aims to answer are: * Does doxycycline have a significant anti-fibrosis role when given as adjuvant therapy to TB patients with advanced pulmonary TB in a double blind randomized placebo controlled trial? * How does long term respiratory function defer between patients who received adjuvant doxycycline aimed at prevention of TB associated lung fibrosis and those who received a placebo in a double blind randomized controlled trial? Participants will be subjected to the following: * Experimental arm: Doxycycline 100 mg once daily for 12 weeks administered concurrently with standard of care anti-TBs. * Comparator arm: Placebo once daily for 12 weeks administered concurrently with standard of care anti-TBs. |
MAKERERE UNIVERSITY | 2025-04-17 |
| 135 | Prevalence of Multidrug Resistant Tuberculosis By Xpert MTB/RIF Ultra and Xpert XDR Assay Among Newly Diagnosed Cases PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is one of the major public health threats, competing with the human immunodeficiency virus (HIV) as the cause of death due to infectious diseases worldwide. Multi drug-resistant Mycobacterium tuberculosis (MDR-TB) is one of the leading causes of death in the world. The resource constraints make it difficult to diagnose and monitor the cases of MDR-TB. GeneXpert is a recognized tool used to diagnose the patients of pulmonary tuberculosis in clinical settings across the globe MDR Multidrug-resistant tuberculosis (MDR-TB), … |
FATMA NASHAT ESMAIL ZYADA; | 2025-11-01 |
| 136 | Enhanced Diagnostic Workup for Patients About to Start Empiric Tuberculosis Treatment in Lusaka, Zambia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being conducted to determine whether in patients who are diagnosed with tuberculosis on a clinical basis (where tuberculosis is not found in the sputum) might have other lung diseases than tuberculosis. Depending on the precise nature of your complaints, additional investigations shall be requested by the study investigators. Possible additional investigations will include laboratory tests on samples of your blood, an additional chest X-ray, lung function testing (where you will have to blow air into a machine, so that your lung capacity is registered), CT-scan, … |
T.W. HOFFMAN; | 2025-07-14 |
| 137 | Observation Study on The Efficacy of Yiqi Gubiao Pill in The Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis: A Double-Blind Randomized Controlled Trial Protocol PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis-related obstructive pulmonary disease (TOPD), as a high-burden disease in most countries, poses difficulties in the diagnosis and treatment of the disease when coexisting, and increases the risk of death for patients. Preliminary studies have shown that Yiqi Gubiao Wan has significant effects in relieving cough, alleviating asthma, expectorating phlegm, and delaying airway obstruction. The purpose of this study is to verify the therapeutic effect of Yiqi Gubiao pill on patients with TOPD through rigorous methodological design and to evaluate its safety. We will conduct a prospective, double-blind, randomized controlled trial. First, … |
JIN DAI; | 2025-03-31 |
| 138 | A Pragmatic Open-label, Community-based, Cluster Randomised Controlled Superiority Trial to Evaluate The Efficacy and Cost-effectiveness of Digital Data Linkage and Scheduling (‘C-it’) With or Without Community Data Use (‘DU-it’) to Increase Antenatal Clinic Uptake in Western Kenya PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators propose to increase ANC uptake through a health systems strengthening approach that links digital data platforms and trains community Work Improvement Teams (WITs) to use these data to identify problems and come up with local solutions. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey ‘seeing’ linked data (C-it) and ‘doing’ or acting on the data (DU-it). The trial design is a 2-arm, … |
MIRIAM TAEGTMEYER; | 2025-06-27 |
| 139 | Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an investigational, prospective, multicenter, single-arm, open label trial. The goal of this clinical trial is to evaluate the efficacy and safety of a 6-month all-oral regimen, consisting of Bedaquiline (BDQ, B), Delamanid (DLM, D), Linezolid (LZD, L), Levofloxacin (LFX) or Clofazimine (CFZ, C), or BDLLfxC regimen, … |
WEN-HONG ZHANG; | 2025-09-02 |
| 140 | Validation and Simplification of The Retinol Isotope Dilution Technique in Burkinabe Schoolchildren PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Two cross-sectional, repeated-pass, community-based studies will be carried out during the school year. The first study will be conducted from November to December. This period corresponds to the end of the rainy season and the end of the mango season, which is one of the main sources of vitamin A in the Orodara region. The second survey will be carried out 5 to 6 months (April-May of the following year) after data collection for the first study, … |
AUGUSTIN N. ZEBA; | 2025-03-18 |
| 141 | Structured Peer-delivered Antiretroviral Therapy (ART) and Reentry Community Strategy to Overcome Barriers to HIV Care Continuity During Community Re-entry From Incarceration in South Africa PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The overarching goal of this study is to implement a transition community adherence club strategy (Full-SPARCS) for HIV-positive individuals transitioning from correctional to community settings in South Africa. The investigators seek to provide actionable findings to inform policy decisions to contribute to HIV care continuity with this population. The investigators note that effectiveness and scalability often conflict with intervention design; thus, … |
CHRISTOPHER HOFFMANN; | 2026-02-11 |
| 142 | Evaluating Novel Pediatric Pulse Oximeters for Outpatient Child Pneumonia Care in Sub-Saharan Africa PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this clinical trial is to evaluate the performance of three pulse oximeters during outpatient care within Cape Town, South Africa. This objective will be achieved through generating evidence on how, why, for whom, … |
ERIC MCCOLLUM; | 2025-12-03 |
| 143 | Work Productivity Losses in The United States Among High-risk Patients With COVID-19 During Acute and Longer-term Follow-up in An Omicron Predominant Period (PULSE-US) PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to understand how COVID-19 affects people’s ability to work and to calculate the costs associated with loss of work. The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming severe. The two groups are: People who took the antiviral medication nirmatrelvir-ritonavir (also called Paxlovid) People who were eligible to receive antiviral medication but did not receive any. The participants will be selected from various health databases in the US between June 2021 and December 2022. The main goals are: To look at the characteristics of both groups of participants with COVID-19. To measure how much work these participants missed, including days off and sick leave, and the costs associated with this work loss. To compare work loss and costs between the two groups of participants, considering differences in their clinical and demographic characteristics. The study will evaluate at least 30 days of data from participants after they are confirmed to have COVID-19 |
PFIZER | 2026-02-09 |
| 144 | Effects of Tuberculosis Infection on Placental Development and Function PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to understand how tuberculosis (TB) infection impacts the function and development of the placenta, and whether TB infection can contribute to pregnancy-related disorders through effects on the placenta. The main questions it aims to answer are: * Does TB infection affect the structure of the placenta? * Does TB infection affect the function of the placenta? Pregnant women attending delivery clinics in Addis Abeba, Ethiopia, … |
PER BJORKMAN; | 2025-03-17 |
| 145 | Detection of Mycobacterium Tuberculosis in Blood of TB Patients and Their Contacts in Uganda PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Mycobacterium tuberculosis (Mtb) is a major human pathogen, responsible for an estimated 10.6 million cases of active tuberculosis (TB) and 1.6 million deaths in 2021. Most adult cases of active TB arise from progression of latent tuberculosis infection (LTBI), whose global prevalence is estimated at 23%. Preventive therapy (e.g. a 6-month course of the anti-TB drug isoniazid) is effective in reducing risk of progression from LTBI to active TB. Global roll-out of preventive therapy will be required to achieve the World Health Organization target of TB elimination by 2050, … |
ADRIAN MARTINEAU; | 2025-03-12 |
| 146 | Improving The Outcomes of Children with Tuberculosis Through Innovative Diagnostics and Treatment Monitoring PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims at identifying and evaluating novel diagnostic methods for children evaluated for respiratory tuberculosis. The investigators will use alternative samples like stool, urine, and masks to diagnose children with respiratory tuberculosis. Once diagnosed, the investigators will use target next generation sequencing to determine if the bacillus is resistant to any of the drugs used for treatment. Additionally, children initiated under TB treatment will be followed-up during treatment to measure blood biomarkers for outcome prediction. Finally, … |
CHRISTOPH LANGE; | 2025-02-07 |
| 147 | Tuberculosis Case Finding at The Completion of The CoVPN 3008 Clinical Trial: A Substudy to CoVPN 3008 PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This substudy aims to identify cases of tuberculosis after the CoVPN 3008 clinical trial is completed. |
COVID 19 PREVENTION NETWORK | 2026-01-26 |
| 148 | Cardiometabolic Risk Factors Associated With Multidrug-Resistant Tuberculosis: A Case-Control Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: MDR-TB (Multidrug Resistant tuberculosis) remains a major public health concern, especially in high-burden countries like Nepal. While individual risk factors are known, the cumulative impact of cardiometabolic on MDR-TB is not well understood. Methods and Findings: A health-facility-based, age- and sex-matched 1:2 case-control study will be conducted at DR-TB (Drug Resistant Tuberculosis) treatment centers in Gandaki Province, Nepal. MDR-TB patients (cases) and DS-TB patients (controls) will be enrolled. Cases will be defined as adults (≥18 years) with confirmed MDR-TB; controls will be adults with sputum-positive DS-TB (Drug Sensitive Tuberculosis). Data on sociodemographics, cardiometabolic risk factors (alcohol, tobacco, BMI, hypertension, … |
SISHIR POUDEL; | 2025-06-26 |
| 149 | Treatment of Moderate-to-severe Papulopustular Rosacea With Deucravacitinib PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This will be a double-blind, randomized placebo-controlled study in which participants will be randomized 2:1 to receive 6 mg deucravacitinib or placebo once daily for 8 weeks, followed by an open label extension during which all participants will receive 6 mg deucravacitinib once daily for an additional 8 weeks. The open-label extension has been incorporated in order to ensure all participants receive benefit from the study, as well as to benefit from the intra-patient comparison of placebo to drug, … |
BENJAMIN UNGAR; | 2026-01-01 |
| 150 | Analysis of The Clinical Characteristics and Three Treatment Methods of Granulomatous Lobular Mastitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Granulomatous lobular mastitis (GLM) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment. This study aims to analyze the clinical characteristics and demographic data of GLM patients and to compare the overall effectiveness of three treatment methods: surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy, with the goal of providing new insights for clinical treatment. |
FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY | 2024-10-19 |
| 151 | Phase 1b/2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN/MDS Overlap or High-Risk CMML PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS) overlap or high risk chronic myelomonocytic leukemia (CMML). Axatilimab is an antibody that is cloned from a single white blood cell that is known to be able to recognize cancer cells and block a protein on the surface of the white blood cells that may be involved in cancer cell growth. By blocking the proteins, … |
UMA BORATE; | 2026-03-13 |
| 152 | Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes. |
JOHN Z METCALFE; | 2026-01-26 |
| 153 | Impact of Capacity Building of Healthcare Workers on Management of Post-Traumatic Stress Disorder Among Road Traffic Injury Patients in Hospitals in Fako Division, Cameroon PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a community- and hospital-based interventional study consisting of two interventions: * Capacity building of healthcare workers (HCWs) in the intervention group (Buea Regional Hospital, selected by simple random sampling-balloting method) on management of post-traumatic stress disorder (PTSD) among road traffic injury (RTI) patients (victims). This intervention will be evaluated using pre/posttest scores via a questionnaire to be administered to HCWs to assess change in knowledge and comfort level in PTSD management and 6 months of follow-up to assess change in practice (number of RTI patients screened for PTSD and number of identified PTSD cases referred for treatment to mental health specialists) after the capacity building. * Also, a pre/post quasi-experimental study design without a control group where psychotherapy will be used in a 6-month follow-up of RTI patients diagnosed with PTSD. The participants (RTI patients diagnosed with PTSD) that will be used for this pre/post quasi-experimental study using psychotherapy will come from the baseline study where the prevalence of PTSD among RTI victims will be determined. The goal of this clinical trial is to learn if capacity building of healthcare workers on the management (screening, treatment, and referral) of post-traumatic stress disorder (PTSD) among road traffic injury (RTI) patients in hospitals leads to change in knowledge and comfort level of healthcare workers in screening and timely management of PTSD to improve patients’ outcomes. Given that attention to care for RTI victims in hospitals in Cameroon and Fako Division in particular is focused on physical care, this study seeks to ensure the provision of holistic care to RTI victims in hospitals, which is in line with the definition of health (comprising the mental, physical, and social well-being of individuals and not just the mere absence of disease or infirmity) by the World Health Organization (WHO). This study will also, through the pre/post quasi-experiment without a control group, learn about the feasibility of using/integrating psychotherapy alongside timely screening for PTSD in routine RTI patient care in primary health care to improve PTSD status in adult RTI patients diagnosed with PTSD in the Cameroonian context. This study aims to answer five research questions: Research Questions 1. What is the epidemiological profile of RTI patients at health facilities in Fako Division from 2019 to 2023? 2. What is the prevalence of PTSD among RTI patients in health facilities in Fako Division? 3. What factors are associated with PTSD among RTI patients in health facilities in Fako Division? 4. What is the standard of PTSD care provided to RTI patients in health facilities in Fako Division? 5. What is the impact of capacity building of healthcare workers on the management of PTSD in RTI patients in health facilities in Fako Division? Researchers will * Describe the epidemiological profile of RTI patients in hospitals in Fako Division, Cameroon, from January 2019 to December 2023, particularly with regard to PTSD screening recommendation and uptake via an exhaustive chart review of medical records. * Determine the prevalence of PTSD among RTI patients via survey using PCL-5 and a cut-off score of at least 33/80. * Assess factors associated with PTSD. * Assess care given to RTI patients and identify barriers, particularly regarding PTSD management. * Compare pre/posttest scores (at baseline-T0, post-training-T1, and 30 days post-training-T2) of healthcare workers’ knowledge and comfort level in PTSD management following capacity building of HCWs on PTSD management to see if there is change in knowledge and comfort level due to the capacity-building intervention in the randomly selected hospital chosen as the intervention group (Buea Regional Hospital) and also establish if the knowledge was sustained after 30 days. * Collect data at 1, 3, and 6 months of follow-up on the number of RTI patients screened for PTSD by trained health workers during 6 months of post-training follow-up and the number of timely referrals of PTSD cases identified, and compare these to what was obtained before the training (baseline) and establish if there is a change. * Collect data on the PTSD status of PTSD patients at 1, 3, and 6 months of follow-up with psychotherapy and conclude on the feasibility of including psychotherapy in the Cameroonian context to improve PTSD status. Participants (RTI victims) will: * Be booked for PTSD screening 1 month after RTI, be called up for an appointment to be screened 1 month after RTI, and have diagnosed PTSD cases referred for effective management. * Diagnosed PTSD cases will be followed up with psychotherapy once every 2 weeks for 6 months (12 sessions in total), and PTSD status will be followed up monthly. * Keep a record of symptoms, difficulties/challenges faced in managing PTSD, the number of times they experience PTSD symptoms, and improvement over time. |
NGU CLAUDIA NGEHA; | 2025-08-08 |
| 154 | A Randomized Controlled Trial on Exercise Program in Patients With Nontuberculous Mycobacterial Pulmonary Disease (NTM-Exercise) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: 1.objective Evaluation of effectiveness and safety of exercise intervention program for patients with non-tuberculous mycobacterial pulmonary disease 2. background Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic respiratory infection that generally affects individuals with structural lung diseases, such as chronic obstructive pulmonary disease (COPD) and bronchiectasis and without structural lung disease. The prevalence of NTM-PD is increasing worldwide , … |
YONSEI UNIVERSITY | 2026-04-03 |
| 155 | Analysis of Liver Injury Risk Factors in A Multiethnic Population Treated With Antituberculosis Drugs PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is the world’s second leading cause of death from a single infectious agent after COVID-19. In 2022, TB was estimated to have affected 10.6 million people, of whom 1.3 million died because of it, despite the WHO’s implementation of the End TB program. Although the gold standard therapy is effective, it may lead to adverse events, among which hepatotoxicity is the most common. Due to its frequency, severity, and potential outcome, anti-TB drug-induced liver injury (DILI) is extremely concerning. Despite decades of use and the large number of patients exposed to anti-TB drugs worldwide, … |
STEFANIA CHELI; | 2024-09-30 |
| 156 | A Survey on The Practice and Interpretation of Various Diagnostic Tests for Tuberculous Pleuritis Among Respiratory Physicians PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis is a major infectious disease with a high mortality burden in the Asia-Pacific region and worldwide. Among various types of extrapulmonary tuberculosis, tuberculous pleuritis (TBP) is amongst the most common manifestations. TBP is also a major underlying cause among patients hospitalised with new-onset unilateral pleural effusion. The workup of TBP frequently involves thoracentesis to retrieve pleural fluid and pleural biopsy for microbiological and histological interpretations. However, the diagnostic accuracy of these tests is of unsatisfactory sensitivity, making diagnosing TBP challenging. In addition, certain tests, including pleural fluid adenosine deaminase (ADA), Mycobacterium tuberculosis polymerase chain reaction (MTB PCR), … |
KA PANG CHAN; | 2026-03-30 |
| 157 | Exploration and Study on The Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are: 1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases. 2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases. |
CHROMX HEALTH | 2025-03-26 |
| 158 | A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate The Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO). |
UCB BIOPHARMA SRL | 2026-03-13 |
| 159 | Evaluating The Accuracy of New Tests for TB Infection Diagnosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Introduction: The large reservoir of tuberculosis infections is a key driver of sustained tuberculosis (TB) incidence. Accurate diagnostic tests are crucial to correctly identify and treat people with TB infection, which is vital to eliminate TB globally. The Cy-TB skin test and STANDARD F TB-Feron FIA (TB-Feron) fluorescent immunoassay are two newly developed TB infection tests, which could offer quality and cost advantages over other commercially available TB infection tests, … |
FREUNDESKREIS FÜR INTERNATIONALE TUBERKULOSEHILFE E V | 2025-03-19 |
| 160 | Preliminary Study of CXCL3 As A Biomarker of Diabetic Kidney Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn about CXCL3 as a biomarker for type 2 diabetic kidney disease (DKD) in adults between age of 18-80. The main question it aims to answer is: – Is CXCL3 elevated in the serum or urine of type 2 adult DKD patients compared to normal control or diabetes mellitus without kidney involvement? – Is CXCL3 elevated in the mRNA of PBMC of type 2 adult DKD patients compared to normal control or diabetes mellitus without kidney involvement? – … |
THE FIRST HOSPITAL OF JILIN UNIVERSITY | 2024-07-30 |
| 161 | Validation of Scoring Systems for Differentiating Intestinal Tuberculosis from Crohn’s Disease Utilizing Clinical, Endoscopic, and Interferon-gamma Releasing Assay in Asian Population PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Differentiating CD from intestinal tuberculosis (ITB) is difficult due to the low sensitivities of currently available diagnostic tests. The Asia-Pacific guideline recommends anti-tuberculous therapy (ATT) for 8-12 weeks in patients with diagnostic uncertainty due to the risk of disseminated tuberculosis if patients with ITB are misdiagnosed with CD, and are prescribed immunosuppressive therapy. However, treatment with ATT has many side effects and may delay treatment in patients with CD, and this may cause severe relapse and developing complications. Many studies found that some clinical, endoscopy, pathology, radiology, and serology findings can help to improve diagnostic accuracy in these patients. However, … |
JULAJAK LIMSRIVILAI; | 2026-03-01 |
| 162 | Increased Tuberculosis Case Detection – A Cluster-randomized Trial Combining Available Resources and Novel Strategies for High Endemic Areas PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: As estimated by the WHO 10.6 million new Tuberculosis (TB) cases were identified in 2022- while more than three million went undetected and untreated. The low detection rate illustrates the failure to recognise and diagnose TB in the current cascade of healthcare and is a major obstacle to effective TB control programs. This multi-centre cluster-randomised clinical trial will evaluate the effect (i.e., … |
FRAUKE RUDOLF; | 2025-10-03 |
| 163 | A Study to Evaluate The Safety and Efficacy of Bimekizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17 or IL-23 Therapies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleukin IL-17A or 23. |
MARK LEBWOHL; | 2025-11-20 |
| 164 | Validation of Treatment Decision Algorithms for Childhood Tuberculosis at District Health Care Levels in Mozambique and Zambia – The Decide-TB Cluster-randomized Pragmatic Trial PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The Decide-TB project aims to generate evidence for the implementation of a comprehensive Treatment Decision Algorithms (TDA) based approach for TB in children living in high TB burden and resource-limited countries, at District Hospital (DH) and Primary Health Centre (PHC) levels, and to facilitate the integration of this evidence within practices and policies. This programmatic pilot led by the National TB Programs (NTP) will test a TDA-based approach integrating TB screening, diagnosis, treatment decision-making, and disease severity assessment for shorter treatment eligibility, … |
CHISHALA CHABALA; | 2026-03-24 |
| 165 | TUTT-PT: Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: In 2023, the South African Department of Health introduced targeted universal TB testing (TUTT) at antiretroviral therapy (ART) initiation (irrespective of the presence of TB symptoms). Guidelines regarding TPT initiation in the setting of TUTT are conflicting – recommending either (1) delaying TPT initiation for all patients until a negative TB test result is returned2 or (2) delaying TPT only for those patients with a positive TB symptom screen. The new TUTT approach along with ambiguity in the timing of TPT initiation has the potential to substantially reduce timely TPT initiation – … |
CHRISTOPHER HOFFMANN; | 2025-06-28 |
| 166 | HIV Infection Accompanied By Multi-Drug Resistant Tuberculosis: A Decadal Systematic Review and Meta-Analysis PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to investigate the relationship between HIV infection and multi-drug resistant tuberculosis (MDR-TB) among affected individuals in Zahedan, Iran. It will involve a detailed analysis of patient demographics, clinical characteristics, and treatment outcomes to enhance understanding of this co-infection. The findings may inform better treatment strategies and healthcare policies for managing these diseases in similar populations. |
HAMIDREZA KOUHPAYEH; | 2024-09-03 |
| 167 | Comparative Efficacy of Chest Ultrasound, Chest X-Ray and Computer-aided Diagnostic (CAD) for Tuberculosis Diagnosis in Low-Resource Setting: A Cross-Sectional Study From Ethiopia (CUSTB) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Pulmonary Tuberculosis (TB) remains a significant global health concern, particularly in low- and middle-income countries (LMIC), where resources for healthcare are often limited. While CXR is the standard imaging modality for TB diagnosis, its sensitivity and specificity can vary depending on factors such as the stage of the disease and the quality of the image obtained. This study endeavors to assess the diagnostic precision of Chest Ultrasound (CUS) relative to Chest X-ray (CXR) and CAD score in the detection of Pulmonary Tuberculosis (TB) among both index cases and household contacts. |
FRANCESCO DI GENNARO; | 2025-04-30 |
| 168 | Assessment of The Prevalence and The Outcome of Prescribing Drugs Known to Have Major Drug-Drug Interactions With Anti-tuberculous Drugs Among Kasr Alainy Tuberculous Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess the prevalence and the outcome of prescribing drugs known to have major drug-drug interactions with anti-tuberculous drugs among Kasr Alainy tuberculous patients. |
OMNIA AZMY NABEH; | 2025-02-15 |
| 169 | Respiratory Muscle Stretching As An Adjunct to Pulmonary Rehabilitation: Outcomes in Chest Expansion, Dyspnea, and Cough in Post-Tuberculosis Bronchiectasis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study intends to examine the effectiveness of adding RMS to a traditional program of pulmonary rehabilitation regarding chest expansion, dyspnea, and cough symptoms in bronchiectasis post-tuberculosis patients. Bronchiectasis, resulting from tuberculosis treatment, is characterized by restricted chest wall motility, chronic dyspnea, and an irritating cough, factors that severely impair these patients’ quality of life. It is assumed that RMS improves the compliance of the chest wall, thereby enhancing respiratory mechanics and consequently reducing symptoms. The outcomes will be compared between two groups: one group with standard pulmonary rehabilitation and another group with additional RMS exercises. |
DIAN MARTA SARI; | 2024-11-25 |
| 170 | Performance of Xpert MTB/RIF and XDR Assay for Diagnosis of Pulmonary Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: To determine how accurate Xpert MTB/RIF and XDR for diagnosis of pulmonary TB and Rifampicin resistance |
MOHAMED ESMAT MOHAMED KOTB; | 2025-05-23 |
| 171 | Diagnostic Innovations for Pediatric Tuberculosis in Bolivia PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Pediatric tuberculosis (TB) continues to pose diagnostic challenges in low- and middle-income countries with high rates of TB disease, due to the well-described impact of paucibacillary disease in children, and current TB culture and polymerase-chain reaction tests are of limited usefulness due to cost, restricted availability, and poor sensitivity in specimens available from younger children. Our team of experts from Tulane, Johns Hopkins University, Universidad Peruana Cayetano Heredia, … |
RICHARD A. OBERHELMAN; | 2025-09-05 |
| 172 | Comparative- and Cost-effectiveness Research Determining The Optimal Intervention for Advancing Transgender Women Living With HIV to Full Viral Suppression PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal and most cost-effective intervention for advancing trans women living with HIV to full viral suppression. Participants will be randomized (1:1:1) to Peer Health Navigation (PHN) alone, SMS (text messaging) alone, or PHN+SMS. Participants in the PHN alone and PHN+SMS arms will receive unlimited navigation sessions over 3 months. Participants in the SMS alone and PHN+SMS arms will receive 3 daily theory-based text messages for 90 days for a total of 270 unique scripted messages. |
CATHY J REBACK; | 2026-02-11 |
| 173 | Is The Betwixt Application Effective and Acceptable in Improving Emotion Regulation for An Adult Clinical Population? Related Papers Related Patents Related Grants Related Experts Highlight: Title Is the Betwixt application effective and acceptable in improving emotion regulation for an adult clinical population? Short title Betwixt: Effective/acceptable clinical population emotion regulation? Chief Investigator Jacob Andrews Aims A: Evaluate the effectiveness of the Betwixt intervention on emotion regulation, self-compassion, and cognitive reappraisal in a clinical population. B: Investigate whether changes in processes targeted by Betwixt result in improvements in clinical outcomes. C: Explore the acceptability, … |
JACOB ANDREWS; | 2025-05-06 |
| 174 | Retrospective Evaluation of The Efficacy and Safety of Micronized Adipose Tissue Obtained With The Matrigen Device in The Treatment of Patients With Interstitial Cystitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Interstitial cystitis (IC) is a chronic, urological condition characterized by bladder pain, and persistent urinary symptoms. Its complex pathophysiology involves autoimmune mechanisms, urothelial barrier dysfunctions, alterations in sensory neural pathways, and degradation of connective tissue. Epidemiological data show a significant prevalence, often affecting adults of working age and disproportionately impacting women, with a major effect on quality of life. Conventional treatments-including behavioral modifications, pharmacotherapy, and invasive procedures-frequently fail to provide lasting relief, underscoring the need for alternative therapeutic strategies. Regenerative medicine has emerged as a promising field capable of targeting the underlying pathophysiology of chronic diseases. Among its tools, … |
ANTONIO LUIGI PASTORE; | 2025-08-05 |
| 175 | A Clinical Study Comparing The Immune Response to Revaccination With Intradermal BCG and Aerosol BCG in Previously BCG Vaccinated Healthy Adult Volunteers With and Without Type 2 Diabetes PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to: 1. explore whether investigators can make BCG more effective by giving it in a different way. For this, aerosol inhaled BCG will be compared against the conventional BCG injection. 2. explore if there are differences in response to re-vaccination in healthy volunteers with and without Type 2 Diabetes. It will involve 36 previously BCG-vaccinated participants. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity. |
HELEN MCSHANE; | 2025-11-19 |
| 176 | Evaluation of A Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is an infectious disease that is caused by bacteria (bugs). The infection is passed on when a patient with active lung TB coughs bugs into the air, which are then breathed in by an uninfected person. In 90% of people who get infected, the TB infection remains dormant and the person never falls ill with active TB disease. However, 10% of people with dormant TB infection will eventually go on to develop active TB disease at some time in the future, … |
QUEEN MARY UNIVERSITY OF LONDON | 2026-02-20 |
| 177 | Detection of Lipoarabinomannan in Urine, Evaluation of The STANDARDTM F TB LAM FIA and Its Impact on The Initial Diagnosis of TB PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Evaluation of the performance of an in vitro test, the STANDARDTM F TB LAM Ag FIA (SD BIOSENSOR, INC.) for the early diagnosis of tuberculosis (TB) infection. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of tuberculosis infection. The test will be used according to the instructions for use (IFU). |
DANIELA MARIA CIRILLO; | 2025-10-01 |
| 178 | Mediastinal Endobronchial Ultrasound Bronchoscopy Cryobiopsy Study In Sweden PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant’s samples are compared to each other. The investigators conduct EBUS TBNA and EBUS TBMCB on all the study participants.The cryobiopsy samples are numbered to evaluate the number of biopsies needed to reach a definite diagnosis and to assess the added value of every sample taken from the same participitant. Every participitant’s own samples are compared to each other and added value of EBUS TBMCB is defined as the difference in diagnostic yield between the EBUS TBNA alone and the combination of EBUS TBNA with EBUS TBMCB. Diagnostic yield is defined as the efficacy of the investigation module in reaching a definite diagnosis (percentage of cases with a definite diagnosis). Follow up four weeks after the procedure to assess the risk for postoperative complications. |
HAMID AKBARSHAHI; | 2025-07-17 |
| 179 | Fecal Transplantation in Patients With Colonic Diverticulitis: A Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to investigate the safety and effect of fecal microbiome transplantation (FMT) in patients with a former episode of acute colonic diverticulitis. The main question[s] it aims to answer are: – Is FMT in patients with a former episode of acute colonic diverticulitis a safe procedure without severe adverse events – What is the impact of FMT on patient-reported outcomes and re-admission rate Participants will be asked to: – to ingest either 25-30 capsules with FMT or placebo capsules – Fill-in GI-QLI questionnaire prior to treatment/placebo and 3 months post baseline – … |
THOMAS BJØRSUM-MEYER; | 2024-12-31 |
| 180 | Role of Conservative Management in Adhesive Intestinal Obstruction Versus Operative Management PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the role of Conservative management in patients with adhesive Intestinal Obstruction Regarding the selection criteria of the patients, duration of conservative route, success rate, and recurrence of adhesions and avoiding the surgical route complications. |
OSAMA KHALED AHMED; | 2025-03-11 |
| 181 | Mobile Health and Oral Testing to Optimize Tuberculosis Contact Tracing in Colombia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The overall objective of this Aim is to design and iteratively adapt a home-based, mHealth- and oral testing facilitated strategy for implementing tuberculosis (TB) contact tracing in Cali, Colombia. Investigators will employ an iterative, community-engaged, participatory co-design process to optimize the feasibility, acceptability, usability, and appropriateness of the mobile health (mHealth) and oral testing strategy, in preparation for a future, appropriately powered implementation-effectiveness trial. This protocol includes the baseline contact tracing protocol and the procedures for determining adaptations to the mHealth strategy (i.e., nominal group technique). |
J. LUCIAN DAVIS; | 2025-10-09 |
| 182 | Effect of Immunosuppressants With Adalimumab Biosimilars Vs Corticosteroids on Noninfectious Uveitis: A Multicenter, Randomized, Non-inferiority Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multi-center, prospective, randomized controlled non-inferior clinical study. A total of 120 subjects with non-infectious intermediate, posterior, or panuveitis were enrolled in Zhongshan Ophthalmic Center and three other centers. They were randomly assigned to the experimental group and the control group according to ( 1 : 1 ). We hypothesized that adalimumab biosimilars combined with immunosuppressive agents in the treatment of non-infectious uveitis is not inferior to glucocorticoids combined with immunosuppressive agents, and there are no additional adverse events and safety issues. |
WEI CHI; | 2025-05-23 |
| 183 | A Phase 1, Open-Label, Drug-Drug Interaction Study to Assess The Effect of TAK-279 on The Pharmacokinetics of A Sensitive CYP3A4 Substrate and A Sensitive CYP2C8 Substrate in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of this study is to find out how several doses of TAK-279 affects the body of healthy adults and processes midazolam and repaglinide (pharmacokinetics or PK). Another aim is to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults either alone or together with midazolam or repaglinide. During the study, participants will need to stay at the clinic for 19 days. Blood samples will be taken at several timepoints during the study. The study drug will be given by mouth (orally). |
MARA BAIER; | 2024-05-16 |
| 184 | A Phase 1a, Dose-finding, Open-label Trial Followed By A Phase 1b, Double-blind, Randomised, Placebo-controlled Trial to Evaluate The Safety, Reactogenicity, and Immunogenicity of The Tuberculosis Subunit Vaccine H107e/CAF®10b in Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) is an infection caused by bacteria passed from one person to another through the air when an infected person for instance coughs, speaks, or sneezes. This study tests the safety and vaccine-induced immune response of a new preventive TB vaccine called H107e/CAF®10b. H107e is a copy of protein parts from the bacterium causing tuberculosis, Mycobacterium tuberculosis, … |
STATENS SERUM INSTITUT | 2026-03-10 |
| 185 | Interferon Gamma, Interleukin-10, Hematology and Microscopic Profile of Tuberculosis Patients With Treatment Combination of Anti-Tuberculosis and Butterfly Pea Flowers Extract (Clitoria Ternatea) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if butterfly pea flowers (Clitoria ternatea) decocta extract works to treat as adjuvant therapy for tuberculosis in adults. It will also learn about the safety of butterfly pea flowers decocta extract. The main questions it aims to answer are: – Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the profiles of interferon gamma and interleukin-10 of people with tuberculosis? – Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the hematology profiles of people with tuberculosis? – … |
MAYA DIAN RAKHMAWATIE; | 2024-08-31 |
| 186 | Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tuberculosis (TB) remains a significant public health concern in Thailand and globally, especially in tropical regions, with pulmonary TB being predominant. Besides affecting the lungs, TB can also impact extrapulmonary organs. Standard TB treatment involves a combination of drugs administered for at least 6 months, but it can cause adverse effects such as hepatitis. Hepatotoxicity, occurring in 20-60% of patients, is commonly linked to isoniazid, rifampicin, and pyrazinamide. Slow acetylators of the NAT2 gene are particularly susceptible. Previous research suggests N-acetylcysteine (NAC) may mitigate hepatotoxicity, … |
WATCHARASAK CHOTIYAPUTTA; | 2024-09-18 |
| 187 | Treatment Development for Smoking Cessation and Engagement in HIV/TB PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV/TB treatment outcomes among individuals with HIV and/or TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV/TB treatment outcomes among patients with HIV and/or TB in resource limited South African settings. |
CONALL O’CLEIRIGH; | 2026-02-09 |
| 188 | Silicosis and Silicotuberculosis Among Small Scale Gemstone Miners in Northern Tanzania: SilicoTB PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Artisanal, small-scale mining (ASM) is a large and essential component of the world’s economy. Despite attendant risks, there is little research into risks to the health of artisanal miners. The tanzanite gemstone is mined exclusively in Northern Tanzania, in deep shafts using ASM techniques. There is concerning evidence that the burden of silicosis and tuberculosis (TB) amongst miners is high. In addition to miners’ personal risks, … |
PATRICK HOWLETT; | 2025-12-01 |
| 189 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial to Assess The Prophylactic Efficacy, Safety, and Immunogenicity of The Investigational M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine When Administered Intramuscularly on A 0,1-month Schedule to Adolescents and Adults PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The study is a randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mtb vaccine when administered intramuscularly (IM) on a 0,1-month schedule to adolescents and adults. This trial will be conducted in 3 cohorts: Interferon gamma release assay (IGRA)-positive Cohort, IGRA-Negative Cohort and Human Immunodeficiency virus (HIV) Cohort. |
GATES MEDICAL RESEARCH INSTITUTE | 2026-02-12 |
| 190 | The Effect of Stress Ball Intervention During Non-Stress Test on Anxiety and Fetal Well-Being in Women With High-risk Pregnancy: A Randomized Controlled Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This research will be conducted to determine the effect of stress ball intervention during NST on anxiety and fetal well-being in high-risk pregnant women. Women with high-risk pregnancies randomly assigned to intervention (n=43) and control (n=43) groups at a state and a faculty hospital in Turkey will be included in the study. Pregnant women in the intervention group will be told to squeeze and release the ball once after counting to three, to inhale each time they press the ball, … |
HÜMEYRA TÜLEK DENİZ; | 2024-08-31 |
| 191 | A Feasibility Study of A Controlled Human Infection Model (CHIM) With Intradermal Bacillus Calmette-Guérin (BCG) Injection in Malawi PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Despite tremendous efforts, an effective tuberculosis (TB) vaccine remains elusive. TB continues to infect and kill many. In 2021, TB infected more than 10 million and killed 1.6 million people. To date, the M.bovis bacille Calmette Guerin (BCG) is the only licensed vaccine against tuberculosis (TB). Efforts to come up with new and effective vaccines have not been successful. Partially, the lack of suitable disease models and protection correlates hinders the research of new vaccines. Controlled human infection model studies (CHIM) involve administering disease-causing microbes to healthy individuals, … |
STEPHEN GORDON; | 2026-03-01 |
| 192 | Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A randomized control trial open level and parallel design was conducted in the department of paediatrics, Bangladesh Medical University (BMU). All diagnosed cases of Refractory Polyarticular JIA according to ILAR criteria, unresponsive to MTX were enrolled in this study. After getting written informed consent from the parents/legal guardians, … |
MD MAHBUBUR RAHMAN; | 2026-02-23 |
| 193 | Local Dishes Versus Ready-to-use Therapeutic Foods in The Management of Severe Acute Malnutrition During The Rehabilitation Phase: A Randomized, Single-blind Study at The Regional Hospital Annex of Mokolo (Cameroon) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In a context of frequent shortages of ready-to-use therapeutic foods (RUTFs), this study aimed at assessing the effectiveness of the use of local dishes in conjunction with nutritional education for children with severe acute malnutrition (SAM) during the rehabilitation phase. This work is based on a randomized, single-blind study. Children aged between 6 to 59 months, hospitalized for SAM and undergoing treatment during the rehabilitation phase, were included. Randomization was performed by consecutive inclusion based on: – Even numbers (control group under RUTFS) and – Odd numbers (intervention group with local dishes). |
KAMO SELANGAI HÉLÈNE; | 2024-04-25 |
| 194 | ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will compare community-delivered, multi-month dispensing of tuberculosis preventive therapy (TPT) to standard-of-care clinic-based TPT delivery in a population of South African adults who are recommended to receive TB preventive therapy. We hypothesize that persons receiving multi-month dispensing of TPT in the community will have a higher rate of TPT completion at 3 months than persons receiving TPT via standard of care with monthly clinic-based refills. |
ADRIENNE E SHAPIRO; | 2026-01-02 |
| 195 | Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A5406 hypothesizes that dolutegravir (DTG) 50 mg taken twice daily will provide adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated TB. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2025-12-08 |
| 196 | A Prospective Standardized Assessment of People With Cystic Fibrosis and Non-tuberculosis Mycobacteria Pulmonary Disease Undergoing Treatment With Mycobacteriophage (POSTSTAMP) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in killing the mycobacteria. Individuals who are found to have at least one phage will be offered assistance in pursuing FDA approval for treatment via expanded-access Individual New Drug (IND) for compassionate-use. They will receive phage treatment for 1 year along with their guideline-based antibiotics for NTM. Individuals who are not identified as having a phage match will be followed as they continue to receive guideline based antibiotic therapy for 1 year. All subjects, including those who do not have a phage match will continue to be observed for the duration of the study, or about 1 year. |
JERRY A. NICK; | 2025-05-21 |
| 197 | Phase II Clinical Study of Contezolid for The Treatment of Tuberculous Meningitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Contezolid is a novel oxazolidinone antibiotic developed by Shanghai Mengke Pharmaceutical Co., Ltd., which successfully went public in 2021. It inhibits bacterial growth by interfering with protein synthesis through its translational inhibitory effect on bacteria. Contezolid has demonstrated promising clinical results in patients with drug-resistant tuberculosis, making it a powerful tool in the fight against drug-resistant tuberculosis. Currently, there is a lack of pharmacokinetic data on contezolid in patients with central nervous system tuberculosis. Some studies have reported the steady-state concentrations of contezolid in the serum and cerebrospinal fluid (CSF) of tuberculous meningitis patients receiving multidrug therapy, … |
NIE WENJUAN; | 2025-02-06 |
| 198 | Phase II Clinical Study of Contezolid for The Treatment of Bone and Joint Tuberculosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Contezolid is a novel oxazolidinone antibacterial agent that has shown promising application prospects in the field of tuberculosis treatment in recent years. Studies have demonstrated that contezolid exhibits comparable anti-tuberculosis activity to linezolid both in vitro and in vivo, and even superior intracellular bactericidal activity against Mycobacterium tuberculosis. More importantly, contezolid significantly reduces the risks of bone marrow suppression toxicity, neurotoxicity, and lactic acidosis compared to linezolid, thereby enhancing the drug’s safety and tolerability. In the treatment of bone and joint tuberculosis, contezolid, as a new anti-tuberculosis drug, holds potential significant value. Firstly, … |
NIE WENJUAN; | 2025-02-06 |
| 199 | Rapid Research in Diagnostics Development for Tuberculosis Network (R2D2 Kids) and Assessing Diagnostics At Point-of-care for Tuberculosis in Children (ADAPT for Kids) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years. The Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and the Assessing Diagnostics at Point-of-care for Tuberculosis in children (ADAPT for Kids) studies seek to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests for use in children. |
ADITHYA CATTAMANCHI; | 2026-03-11 |
| 200 | An Open-Labelled, Phase I Clinical Trial to Assess The Safety Reactogenicity, Tolerability and Immunogenicity of A Tuberculosis Vaccine BBV169 (MTBVAC), in Healthy Indian Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: An Open-labelled, Phase I Clinical Trial to Assess the Safety, Reactogenicity, Tolerability, and Immunogenicity of MTBVAC in healthy Indian adult volunteers A total of 30 subjects with Quantiferon®-TB Gold Plus assay negative and ages 18 to 65 years will be enrolled in this trial. All the subjects will receive a single dose of MTBVAC via the intradermal route in the right deltoid region. DSMB meetings will be conducted after Day 28 , Day 90 \& Day 180 after vaccinating all subjects. |
BHARAT BIOTECH INTERNATIONAL | 2025-05-22 |